

MEDICIS PHARMACEUTICAL CORP

Form 10-Q

August 09, 2011

Table of Contents

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 10-Q**

**QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934**

For the quarterly period ended June 30, 2011

OR

**TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934**

For the transition period from _____ to _____

Commission file number: 001-14471

MEDICIS PHARMACEUTICAL CORPORATION

(Exact name of Registrant as specified in its charter)

Delaware

52-1574808

(State or other jurisdiction of
incorporation or organization)

(I.R.S. Employer Identification No.)

7720 North Dobson Road
Scottsdale, Arizona 85256-2740
(Address of principal executive offices)

(602) 808-8800

(Registrant's telephone number, including area code)

Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See the definitions of large accelerated filer, accelerated filer and smaller reporting company in Rule 12b-2 of the Exchange Act.

Large accelerated filer

Accelerated filer

Non-accelerated filer
(Do not check if a smaller
reporting company)

Smaller reporting
company

Indicate by check mark whether the registrant is a shell company (as defined in Exchange Act Rule 12b-2) Yes No
Indicate the number of shares outstanding of each of the issuer's classes of common stock, as of the latest practicable date.

Class

Outstanding at August 3, 2011

Class A Common Stock \$.014 Par Value

63,358,951 (a)

(a) includes 2,046,565 shares of unvested restricted
stock awards

MEDICIS PHARMACEUTICAL CORPORATION
Table of Contents

| | Page |
|--|------|
| <u>PART I. FINANCIAL INFORMATION</u> | |
| <u>Item 1 Financial Statements</u> | 1 |
| <u>Condensed Consolidated Balance Sheets as of June 30, 2011 and December 31, 2010</u> | 1 |
| <u>Condensed Consolidated Statements of Income for the Three and Six Months Ended June 30, 2011 and 2010</u> | 3 |
| <u>Condensed Consolidated Statements of Cash Flows for the Six Months Ended June 30, 2011 and 2010</u> | 4 |
| <u>Notes to the Condensed Consolidated Financial Statements</u> | 5 |
| <u>Item 2 Management's Discussion and Analysis of Financial Condition and Results of Operations</u> | 28 |
| <u>Item 3 Quantitative and Qualitative Disclosures About Market Risk</u> | 49 |
| <u>Item 4 Controls and Procedures</u> | 49 |
| <u>PART II. OTHER INFORMATION</u> | |
| <u>Item 1 Legal Proceedings</u> | 50 |
| <u>Item 1A Risk Factors</u> | 55 |
| <u>Item 6 Exhibits</u> | 56 |
| <u>SIGNATURES</u> | 57 |
| <u>EX-10.1</u> | |
| <u>EX-10.2</u> | |
| <u>EX-10.4</u> | |
| <u>EX-10.5</u> | |
| <u>EX-10.6</u> | |
| <u>EX-10.7</u> | |
| <u>EX-10.8</u> | |
| <u>EX-10.9</u> | |
| <u>EX-31.1</u> | |
| <u>EX-31.2</u> | |
| <u>EX-32.1</u> | |
| <u>EX-101 INSTANCE DOCUMENT</u> | |
| <u>EX-101 SCHEMA DOCUMENT</u> | |
| <u>EX-101 CALCULATION LINKBASE DOCUMENT</u> | |
| <u>EX-101 LABELS LINKBASE DOCUMENT</u> | |
| <u>EX-101 PRESENTATION LINKBASE DOCUMENT</u> | |
| <u>EX-101 DEFINITION LINKBASE DOCUMENT</u> | |

Table of Contents**Part I. Financial Information****Item 1. Financial Statements**

MEDICIS PHARMACEUTICAL CORPORATION
CONDENSED CONSOLIDATED BALANCE SHEETS
(in thousands)

| | June 30, 2011 (unaudited) | December 31, 2010 |
|---|---------------------------------|----------------------|
| Assets | | |
| Current assets: | | |
| Cash and cash equivalents | \$ 150,201 | \$ 218,362 |
| Short-term investments | 655,555 | 485,192 |
| Accounts receivable, net | 166,399 | 130,622 |
| Inventories, net | 30,829 | 35,282 |
| Deferred tax assets, net | 24,602 | 70,461 |
| Other current assets | 19,264 | 15,268 |
| Assets held for sale from discontinued operations | 10,248 | 13,127 |
| Total current assets | 1,057,098 | 968,314 |
| Property and equipment, net | 23,683 | 24,435 |
| Net intangible assets | 197,283 | 195,308 |
| Goodwill | 92,398 | 92,398 |
| Deferred tax assets, net | 95,516 | 36,898 |
| Long-term investments | 22,379 | 21,480 |
| Other assets | 2,991 | 2,991 |
| | \$ 1,491,348 | \$ 1,341,824 |

See accompanying notes to condensed consolidated financial statements.

Table of Contents

MEDICIS PHARMACEUTICAL CORPORATION
CONDENSED CONSOLIDATED BALANCE SHEETS, Continued
(in thousands, except share amounts)

| | June 30, 2011 (unaudited) | December 31, 2010 |
|---|---------------------------------|----------------------|
| Liabilities | | |
| Current liabilities: | | |
| Accounts payable | \$ 45,393 | \$ 41,015 |
| Current portion of contingent convertible senior notes | 169,145 | |
| Reserve for sales returns | 78,220 | 60,692 |
| Accrued consumer rebates and loyalty programs | 124,922 | 101,678 |
| Managed care and Medicaid reserves | 51,239 | 49,375 |
| Income taxes payable | | 4,628 |
| Other current liabilities | 73,764 | 75,228 |
| Liabilities held for sale from discontinued operations | 7,172 | 7,276 |
| Total current liabilities | 549,855 | 339,892 |
| Long-term liabilities: | | |
| Contingent convertible senior notes | 181 | 169,326 |
| Other liabilities | 38,982 | 5,084 |
| Stockholders Equity | | |
| Preferred stock, \$0.01 par value; shares authorized: 5,000,000; issued and outstanding: none | | |
| Class A common stock, \$0.014 par value; shares authorized: 150,000,000; issued and outstanding: 74,272,334 and 71,863,191 at June 30, 2011 and December 31, 2010, respectively | 1,023 | 995 |
| Class B common stock, \$0.014 par value; shares authorized: 1,000,000; issued and outstanding: none | | |
| Additional paid-in capital | 778,120 | 715,651 |
| Accumulated other comprehensive loss | (23,298) | (2,149) |
| Accumulated earnings | 498,907 | 460,716 |
| Less: Treasury stock, 13,059,002 and 12,897,610 shares at cost at June 30, 2011 and December 31, 2010, respectively | (352,422) | (347,691) |
| Total stockholders equity | 902,330 | 827,522 |
| | \$ 1,491,348 | \$ 1,341,824 |

See accompanying notes to condensed consolidated financial statements.

Table of Contents

MEDICIS PHARMACEUTICAL CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF INCOME
(unaudited)
(in thousands, except per share data)

| | Three Months Ended | | Six Months Ended | |
|--|--------------------|------------------|------------------|------------------|
| | June 30, 2011 | June 30, 2010 | June 30, 2011 | June 30, 2010 |
| Net product revenues | \$ 189,819 | \$ 171,734 | \$ 353,715 | \$ 335,326 |
| Net contract revenues | 1,008 | 1,862 | 2,025 | 3,812 |
| Net revenues | 190,827 | 173,596 | 355,740 | 339,138 |
| Cost of product revenues (1) | 18,237 | 16,330 | 32,568 | 31,437 |
| Gross profit | 172,590 | 157,266 | 323,172 | 307,701 |
| Operating expenses: | | | | |
| Selling, general and administrative (2) | 90,393 | 77,091 | 175,023 | 149,375 |
| Research and development (3) | 15,195 | 7,420 | 29,468 | 13,979 |
| Depreciation and amortization | 7,110 | 6,916 | 14,434 | 13,649 |
| Operating income | 59,892 | 65,839 | 104,247 | 130,698 |
| Interest and investment income | (1,238) | (780) | (2,512) | (1,940) |
| Interest expense | 1,141 | 1,061 | 2,199 | 2,119 |
| Other expense, net | | (2) | | 257 |
| Income from continuing operations before income tax expense | 59,989 | 65,560 | 104,560 | 130,262 |
| Income tax expense | 25,477 | 24,632 | 43,363 | 49,316 |
| Net income from continuing operations | 34,512 | 40,928 | 61,197 | 80,946 |
| Loss from discontinued operations, net of income tax benefit | 5,729 | 4,428 | 13,054 | 9,078 |
| Net income | \$ 28,783 | \$ 36,500 | \$ 48,143 | \$ 71,868 |
| Basic net income per share continuing operations | \$ 0.55 | \$ 0.68 | \$ 0.99 | \$ 1.35 |

Edgar Filing: MEDICIS PHARMACEUTICAL CORP - Form 10-Q

| | | | | |
|--|-----------|-----------|-----------|-----------|
| Basic net loss per share – discontinued operations | \$ (0.09) | \$ (0.08) | \$ (0.22) | \$ (0.16) |
| Basic net income per share | \$ 0.46 | \$ 0.61 | \$ 0.78 | \$ 1.19 |
| Diluted net income per share – continuing operations | \$ 0.51 | \$ 0.62 | \$ 0.91 | \$ 1.24 |
| Diluted net loss per share – discontinued operations | \$ (0.09) | \$ (0.08) | \$ (0.22) | \$ (0.16) |
| Diluted net income per share | \$ 0.43 | \$ 0.56 | \$ 0.72 | \$ 1.10 |
| Cash dividend declared per common share | \$ 0.08 | \$ 0.06 | \$ 0.16 | \$ 0.12 |
| Common shares used in calculating: | | | | |
| Basic net income per share | 60,308 | 58,271 | 59,719 | 58,161 |
| Diluted net income per share | 67,140 | 64,395 | 66,347 | 64,294 |
| (1) amounts exclude amortization of intangible assets related to acquired products | \$ 5,266 | \$ 5,184 | \$ 10,718 | \$ 10,368 |
| (2) amounts include share-based compensation expense | \$ 8,705 | \$ 2,070 | \$ 14,989 | \$ 4,957 |
| (3) amounts include share-based compensation expense | \$ 615 | \$ 44 | \$ 1,020 | \$ 100 |

See accompanying notes to condensed consolidated financial statements.

Table of Contents

MEDICIS PHARMACEUTICAL CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(unaudited)
(in thousands)

| | Six Months Ended | |
|---|------------------|---------------|
| | June 30, 2011 | June 30, 2010 |
| Operating Activities: | | |
| Net income | \$ 48,143 | \$ 71,868 |
| Loss from discontinued operations, net of income tax benefit | 13,054 | 9,078 |
| Net income from continuing operations | 61,197 | 80,946 |
| Adjustments to reconcile net income from continuing operations to net cash provided by operating activities from continuing operations: | | |
| Depreciation and amortization | 14,434 | 13,649 |
| Amortization of prior service costs, supplemental executive retirement plan | 400 | |
| Adjustment of impairment of available-for-sale investments | | 260 |
| (Gain) loss on sale of available-for-sale investments, net | (27) | 750 |
| Share-based compensation expense | 16,009 | 5,057 |
| Deferred income tax (benefit) expense | (877) | 7,099 |
| Tax benefit (expense) from exercise of stock options and vesting of restricted stock awards | 1,864 | (269) |
| Excess tax benefits from share-based payment arrangements | (2,872) | (320) |
| Increase in provision for sales discounts and chargebacks | 1,163 | 1,031 |
| Accretion of premium on investments | 2,604 | 1,811 |
| Changes in operating assets and liabilities: | | |
| Accounts receivable | (36,940) | (42,849) |
| Inventories | 4,453 | (10,413) |
| Other current assets | (3,995) | (3,810) |
| Accounts payable | 4,378 | 14,972 |
| Reserve for sales returns | 17,528 | 1,131 |
| Accrued consumer rebates and loyalty programs | 23,244 | 17,053 |
| Managed care and Medicaid reserves | 1,863 | (2,668) |
| Income taxes payable | (4,628) | (13,923) |
| Other current liabilities | (17,338) | (2,282) |
| Other liabilities | 128 | (1,958) |
| Net cash provided by operating activities from continuing operations | 82,588 | 65,267 |
| Net cash used in operating activities from discontinued operations | (9,978) | (5,274) |
| Net cash provided by operating activities | 72,610 | 59,993 |
| Investing Activities: | | |
| Purchase of property and equipment | (2,834) | (3,922) |
| Payments for purchase of product rights | (12,824) | 768 |

Edgar Filing: MEDICIS PHARMACEUTICAL CORP - Form 10-Q

| | | |
|--|------------|-----------|
| Purchase of available-for-sale investments | (474,810) | (273,402) |
| Sale of available-for-sale investments | 112,379 | 41,238 |
| Maturity of available-for-sale investments | 188,865 | 69,515 |
| Net cash used in investing activities from continuing operations | (189,224) | (165,803) |
| Net cash used in investing activities from discontinued operations | | (577) |
| Net cash used in investing activities | (189,224) | (166,380) |
| Financing Activities: | | |
| Payment of dividends | (8,535) | (5,993) |
| Excess tax benefits from share-based payment arrangements | 2,872 | 320 |
| Proceeds from the exercise of stock options | 54,049 | 2,206 |
| Net cash provided by (used in) financing activities | 48,386 | (3,467) |
| Effect of exchange rate on cash and cash equivalents | 67 | (34) |
| Net decrease in cash and cash equivalents | (68,161) | (109,888) |
| Cash and cash equivalents at beginning of period | 218,362 | 207,941 |
| Cash and cash equivalents at end of period | \$ 150,201 | \$ 98,053 |

See accompanying notes to condensed consolidated financial statements.

Table of Contents

MEDICIS PHARMACEUTICAL CORPORATION
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
June 30, 2011
(unaudited)

1. NATURE OF BUSINESS

Medicis Pharmaceutical Corporation (Medicis or the Company) is a leading specialty pharmaceutical company focusing primarily on the development and marketing of products in the United States (U.S.) for the treatment of dermatological and aesthetic conditions. Medicis also markets products in Canada for the treatment of dermatological and aesthetic conditions and began commercial efforts in Europe with the Company s acquisition of LipoSonix, Inc. (LipoSonix) in July 2008.

The Company offers a broad range of products addressing various conditions or aesthetic improvements including facial wrinkles, glabellar lines, acne, fungal infections, hyperpigmentation, photoaging, psoriasis, seborrheic dermatitis and cosmesis (improvement in the texture and appearance of skin). Medicis currently offers 13 branded products. Its primary brands are DYSPORT®, PERLANE®, RESTYLANE®, SOLODYN®, VANOS® and ZIANA®. Medicis entered the non-invasive body contouring market with its acquisition of LipoSonix in July 2008. Beginning in the first quarter of 2011, the Company classifies the LipoSonix business as a discontinued operation for financial statement reporting purposes. See Note 2.

The consolidated financial statements include the accounts of Medicis and its wholly owned subsidiaries. The Company does not have any subsidiaries in which it does not own 100% of the outstanding stock. All of the Company s subsidiaries are included in the consolidated financial statements. All significant intercompany accounts and transactions have been eliminated in consolidation.

The accompanying interim condensed consolidated financial statements of Medicis have been prepared in conformity with U.S. generally accepted accounting principles, consistent in all material respects with those applied in the Company s Annual Report on Form 10-K for the year ended December 31, 2010. The financial information is unaudited, but reflects all adjustments, consisting only of normal recurring adjustments and accruals, which are, in the opinion of the Company s management, necessary to a fair statement of the results for the interim periods presented. Interim results are not necessarily indicative of results for a full year. The information included in this Form 10-Q should be read in conjunction with the Company s Annual Report on Form 10-K for the year ended December 31, 2010.

2. DISCONTINUED OPERATIONS

On February 25, 2011, the Company announced that as a result of the Company s strategic planning process and the current regulatory and commercial capital equipment environment, the Company has determined to explore strategic alternatives for its LipoSonix business including, but not limited to, the sale of the stand-alone business. The Company has engaged an investment banking firm to assist the Company in its exploration of strategic alternatives for LipoSonix. The Company expects the disposal of the LipoSonix business to take place by February 2012 or before. As a result of this decision, the Company now classifies the LipoSonix business as a discontinued operation for financial statement reporting purposes, including comparable period results.

Intangible assets and property and equipment related to LipoSonix were determined to be impaired as of December 31, 2010, based on the Company s analysis of the long-lived assets carrying value and projected future cash flows. As a result of the impairment analysis, the Company recorded a write-down of approximately \$7.7 million related to LipoSonix intangible assets and \$2.1 million related to LipoSonix property and equipment during the three months ended December 31, 2010. The write-down of intangible assets and property and equipment related to LipoSonix represented the full carrying value of the respective assets as of December 31, 2010. Therefore, no depreciation or amortization expense was recognized during the six months ended June 30, 2011 related to the discontinued operations, as the long-lived assets of the discontinued operations were written down to \$0 as of December 31, 2010.

Table of Contents

The following is a summary of loss from discontinued operations, net of income tax benefit, for the three and six months ended June 30, 2011 and 2010 (in thousands):

| | Three Months Ended | | Six Months Ended | |
|---|---------------------|------------------|------------------|------------------|
| | June 30, 2011 | June 30, 2010 | June 30, 2011 | June 30, 2010 |
| Net revenues | \$ 200 | \$ 448 | \$ 356 | \$ 1,397 |
| Cost of revenues | 82 | 196 | 2,456 | 846 |
| Gross profit | 118 | 252 | (2,100) | 551 |
| Operating expenses: | | | | |
| Selling, general and administrative | 5,731 | 3,782 | 11,594 | 7,542 |
| Research and development | 3,302 | 3,091 | 6,648 | 6,601 |
| Depreciation and amortization | | 323 | | 643 |
| Loss from discontinued operations before income tax benefit | (8,915) | (6,944) | (20,342) | (14,235) |
| Income tax benefit | (3,186) | (2,516) | (7,288) | (5,157) |
| Loss from discontinued operations, net of income tax benefit | \$ (5,729) | \$ (4,428) | \$ (13,054) | \$ (9,078) |

The Company includes only revenues and costs directly attributable to the discontinued operations, and not those attributable to the ongoing entity. Accordingly, no interest expense or general corporate overhead costs have been allocated to the LipoSonix discontinued operations. Included in cost of revenues for the six months ended June 30, 2011 was a \$1.9 million charge related to an increase in the valuation reserve for LipoSonix inventory that is not expected to be sold.

The following is a summary of assets and liabilities held for sale associated with the LipoSonix discontinued operations as of June 30, 2011 and December 31, 2010 (in thousands):

| | June 30, 2011 | December 31, 2010 |
|---|------------------|----------------------|
| Cash and cash equivalents | \$ 878 | \$ 629 |
| Accounts receivable, net | 83 | 129 |
| Inventories, net | 3,815 | 4,495 |
| Deferred tax assets, net | 5,191 | 7,328 |
| Other assets | 281 | 546 |
| Assets held for sale from discontinued operations | \$ 10,248 | \$ 13,127 |

| | | | | |
|--|----|-------|----|-------|
| Accounts payable | \$ | 2,228 | \$ | 1,802 |
| Other liabilities | | 4,944 | | 5,474 |
| Liabilities held for sale from discontinued operations | \$ | 7,172 | \$ | 7,276 |

Table of Contents

The following is a summary of net cash used in operating activities from discontinued operations for the six months ended June 30, 2011 and 2010 (in thousands):

| | Six Months Ended | |
|--|------------------|------------------|
| | June 30, 2011 | June 30, 2010 |
| Loss from discontinued operations, net of income tax benefit | \$ (13,054) | \$ (9,078) |
| Depreciation and amortization | | 643 |
| Share-based compensation expense | 1,795 | 327 |
| Decrease in assets held for sale from discontinued operations | 2,879 | 3,563 |
| Decrease in liabilities held for sale from discontinued operations | (1,598) | (729) |
| Net cash used in operating activities from discontinued operations | \$ (9,978) | \$ (5,274) |

Net cash used in investing activities from discontinued operations of \$0.6 million for the six months ended June 30, 2010 represents purchases of property and equipment.

3. SHARE-BASED COMPENSATION

At June 30, 2011, the Company had seven active share-based employee compensation plans. Of these seven share-based compensation plans, only the 2006 Incentive Award Plan is eligible for the granting of future awards.

Stock Option Awards

Stock option awards are granted at the fair market value on the date of grant. The option awards vest over a period determined at the time the options are granted, ranging from one to five years, and generally have a maximum term of ten years. Certain options provide for accelerated vesting if there is a change in control (as defined in the plans). When options are exercised, new shares of the Company's Class A common stock are issued.

The total value of the stock option awards is expensed ratably over the service period of the employees receiving the awards. As of June 30, 2011, total unrecognized compensation cost related to stock option awards, to be recognized as expense subsequent to June 30, 2011, was approximately \$1.5 million and the related weighted average period over which it is expected to be recognized is approximately 2.6 years. All of the unrecognized compensation cost related to stock option awards relates to continuing operations.

A summary of stock option activity within the Company's stock-based compensation plans and changes for the six months ended June 30, 2011, is as follows:

| | Number of Shares | Weighted Average Exercise Price | Weighted Average Remaining Contractual Term | Aggregate Intrinsic Value |
|------------------------------|---------------------|--|---|---------------------------------|
| Balance at December 31, 2010 | 6,491,353 | \$ 30.01 | | |
| Granted | 79,933 | \$ 34.30 | | |
| Exercised | (1,984,481) | \$ 27.64 | | |
| Terminated/expired | (80,705) | \$ 36.82 | | |
| Balance at June 30, 2011 | 4,506,100 | \$ 31.01 | 2.7 | \$ 32,807,450 |

Table of Contents

The intrinsic value of options exercised during the six months ended June 30, 2011 was \$16,015,062. Options exercisable under the Company's share-based compensation plans at June 30, 2011 were 4,352,288, with a weighted average exercise price of \$31.18, a weighted average remaining contractual term of 2.6 years, and an aggregate intrinsic value of \$30,957,994.

A summary of outstanding and exercisable stock options that are fully vested and are expected to vest, based on historical forfeiture rates, as of June 30, 2011, is as follows:

| | Number of Shares | Weighted Average Exercise Price | Weighted Average Remaining Contractual Term | Aggregate Intrinsic Value |
|--|-----------------------------|--|--|--|
| Outstanding, net of expected forfeitures | 4,238,744 | \$ 31.19 | 2.7 | \$ 30,085,482 |
| Exercisable, net of expected forfeitures | 4,124,910 | \$ 31.27 | 2.6 | \$ 28,950,668 |

The fair value of each stock option award is estimated on the date of the grant using the Black-Scholes option pricing model with the following assumptions:

| | Six Months Ended | |
|---------------------------------|------------------------------|--------------------------|
| | June 30, 2011 | June 30, 2010 |
| | 0.77% | |
| | to | 1.02% to |
| Expected dividend yield | 0.88% | 1.06% |
| Expected stock price volatility | 0.33 | 0.33 |
| | 2.47% | |
| | to | 2.82% to |
| Risk-free interest rate | 2.81% | 3.04% |
| | 7.0 | |
| Expected life of options | Years | 7.0 Years |

The expected dividend yield is based on expected annual dividends to be paid by the Company as a percentage of the market value of the Company's stock as of the date of grant. The Company determined that a blend of implied volatility and historical volatility is more reflective of market conditions and a better indicator of expected volatility than using purely historical volatility. The risk-free interest rate is based on the U.S. treasury security rate in effect as of the date of grant. The expected lives of options are based on historical data of the Company.

The weighted average fair value of stock options granted during the six months ended June 30, 2011 and 2010, was \$12.25 and \$8.28, respectively.

Restricted Stock Awards

The Company also grants restricted stock awards to certain employees. Restricted stock awards are valued at the closing market value of the Company's Class A common stock on the date of grant, and the total value of the award is expensed ratably over the service period of the employees receiving the grants. As of June 30, 2011, the total amount of unrecognized compensation cost related to nonvested restricted stock awards, to be recognized as expense subsequent to June 30, 2011, was approximately \$40.7 million, and the related weighted average period over which it is expected to be recognized is approximately 3.4 years. Included in the \$40.7 million of total unrecognized compensation cost related to nonvested restricted stock awards is \$2.6 million related to discontinued operations.

Table of Contents

A summary of restricted stock activity within the Company's share-based compensation plans and changes for the six months ended June 30, 2011, is as follows:

| Nonvested Shares | Shares | Weighted Average Grant-Date Fair Value |
|--------------------------------|---------------|---|
| Nonvested at December 31, 2010 | 1,794,445 | \$ 17.94 |
| Granted | 757,310 | \$ 31.47 |
| Vested | (445,912) | \$ 19.11 |
| Forfeited | (25,373) | \$ 23.96 |
| Nonvested at June 30, 2011 | 2,080,470 | \$ 22.54 |

The total fair value of restricted shares vested during the six months ended June 30, 2011 and 2010 was approximately \$8.5 million and \$6.6 million, respectively.

Stock Appreciation Rights

During 2009, the Company began granting cash-settled stock appreciation rights (SARs) to many of its employees. SARs generally vest over a graduated five-year period and expire seven years from the date of grant, unless such expiration occurs sooner due to the employee's termination of employment, as provided in the applicable SAR award agreement. SARs allow the holder to receive cash (less applicable tax withholding) upon the holder's exercise, equal to the excess, if any, of the market price of the Company's Class A common stock on the exercise date over the exercise price, multiplied by the number of shares relating to the SAR with respect to which the SAR is exercised. The exercise price of the SAR is the fair market value of a share of the Company's Class A common stock relating to the SAR on the date of grant. The total value of the SAR is expensed over the service period of the employee receiving the grant, and a liability is recognized in the Company's condensed consolidated balance sheets until settled. The fair value of SARs is required to be remeasured at the end of each reporting period until the award is settled, and changes in fair value must be recognized as compensation expense to the extent of vesting each reporting period based on the new fair value. As of June 30, 2011, the total measured amount of unrecognized compensation cost related to outstanding SARs, to be recognized as expense subsequent to June 30, 2011, based on the remeasurement at June 30, 2011, was approximately \$42.1 million, and the related weighted average period over which it is expected to be recognized is approximately 3.2 years. Included in the \$42.1 million of total measured unrecognized compensation cost related to outstanding SARs is \$5.3 million related to discontinued operations.

The fair value of each SAR was estimated on the date of the grant, and was remeasured at quarter-end, using the Black-Scholes option pricing model with the following assumptions:

| | SARs Granted During the Six Months Ended June 30, 2011 | SARs Granted During the Six Months Ended June 30, 2010 | Remeasurement as of June 30, 2011 |
|---------------------------------|---|---|--|
| Expected dividend yield | 0.87% | 0.95% to 1.06% | 0.84% |
| Expected stock price volatility | 0.32 | 0.32 to 0.33 | 0.31 |
| Risk-free interest rate | 3.12% | 3.04% to 3.07% | 1.76% to 2.50% |

Edgar Filing: MEDICIS PHARMACEUTICAL CORP - Form 10-Q

| | | | |
|-----------------------|-----------|-----------|------------------|
| Expected life of SARs | 7.0 Years | 7.0 Years | 4.7 to 6.6 Years |
|-----------------------|-----------|-----------|------------------|

The weighted average fair value of SARs granted during the six months ended June 30, 2011 and 2010, as of the respective grant dates, was \$9.90 and \$8.14, respectively. The weighted average fair value of all SARs outstanding as of the remeasurement date of June 30, 2011 was \$22.40.

9

Table of Contents

A summary of SARs activity for the six months ended June 30, 2011 is as follows:

| | Number of SARs | Weighted Average Exercise Price | Weighted Average Remaining Contractual Term | Aggregate Intrinsic Value |
|------------------------------|---------------------------|--|--|--|
| Balance at December 31, 2010 | 3,030,142 | \$ 16.99 | | |
| Granted | 64,135 | \$ 27.56 | | |
| Exercised | (272,120) | \$ 15.48 | | |
| Terminated/expired | (166,185) | \$ 15.99 | | |
| Balance at June 30, 2011 | 2,655,972 | \$ 17.46 | 5.2 | \$ 54,994,411 |

The intrinsic value of SARs exercised during the six months ended June 30, 2011 was \$4,937,860.

As of June 30, 2011, 88,455 SARs were exercisable, with a weighted average exercise price of \$14.69, a weighted average remaining contractual term of 4.7 years, and an aggregate intrinsic value of \$1,911,063.

Total share-based compensation expense related to continuing operations recognized during the three months and six months ended June 30, 2011 and 2010 was as follows (in thousands):

| | Three Months Ended | | Six Months Ended | |
|--|------------------------------|--------------------------|------------------------------|--------------------------|
| | June 30, 2011 | June 30, 2010 | June 30, 2011 | June 30, 2010 |
| Stock options | \$ 234 | \$ 385 | \$ 484 | \$ 838 |
| Restricted stock awards | 3,197 | 1,291 | 5,799 | 3,176 |
| Stock appreciation rights | 5,889 | 438 | 9,726 | 1,043 |
| Total share-based compensation expense | \$ 9,320 | \$ 2,114 | \$ 16,009 | \$ 5,057 |

4. SUPPLEMENTAL EXECUTIVE RETIREMENT PLAN

On June 24, 2011, the Company's Compensation Committee adopted the Medicis Pharmaceutical Supplemental Executive Retirement Plan (the "SERP"), a non-qualified, noncontributory, defined benefit pension plan that provides supplemental retirement income for a select group of officers, including the Company's named executive officers. The SERP is effective as of June 1, 2011. Retirement benefits are based on a SERP participant's years of service and average earnings (base salary plus cash bonus or incentive payments) during any three calendar years of service (regardless of whether the years are consecutive), beginning with the 2009 calendar year.

A SERP participant vests in 1/6th of his or her retirement benefit per plan year, effective as of the first day of the plan year, and becomes fully vested in his or her accrued retirement benefit upon (1) the participant's normal retirement date, provided that the participant has at least fifteen years of service with the Company and is employed by the Company on such date, (2) the participant's separation from service due to a discharge without cause or resignation for good reason (as such terms are defined in the participant's employment agreement, or in the absence of such employment agreement or definitions, in the Company's Executive Retention Plan), or (3) a change in control of the Company. A SERP participant accrues his or her retirement benefit based on (x) the participant's number of years of service with the Company (including prior years of service), divided by (y) the number of years designated for such

participant's tier (which ranges from five to twenty years).

Participants in the SERP received credit for prior service with the Company. The prior service accrued benefit of approximately \$33.8 million was recorded as other comprehensive income within stockholders' equity, and is amortized as compensation expense over the remaining service years of each participant. Amortization of

Table of Contents

prior service costs recognized as compensation expense during the three months ended June 30, 2011, was approximately \$0.4 million, representing one month of amortization. The Company also established a deferred tax asset of approximately \$12.0 million, the benefit of which was also recorded in other comprehensive income.

No investments were held by the Company related to the SERP as of June 30, 2011.

5. SHORT-TERM AND LONG-TERM INVESTMENTS

The Company's policy for its short-term and long-term investments is to establish a high-quality portfolio that preserves principal, meets liquidity needs, avoids inappropriate concentrations and delivers an appropriate yield in relationship to the Company's investment guidelines and market conditions. Short-term and long-term investments consist of corporate and various government agency and municipal debt securities. The Company's investments in auction rate floating securities consist of investments in student loans. Management classifies the Company's short-term and long-term investments as available-for-sale. Available-for-sale securities are carried at fair value with unrealized gains and losses reported in stockholders' equity. Realized gains and losses and declines in value judged to be other than temporary, if any, are included in other expense in the condensed consolidated statement of operations. A decline in the market value of any available-for-sale security below cost that is deemed to be other than temporary, results in impairment of the fair value of the investment. The impairment is charged to earnings and a new cost basis for the security is established. Premiums and discounts are amortized or accreted over the life of the related available-for-sale security. Dividends and interest income are recognized when earned. The cost of securities sold is calculated using the specific identification method. At June 30, 2011, the Company has recorded the estimated fair value of available-for-sale securities in short-term and long-term investments of approximately \$655.6 million and \$22.4 million, respectively.

Available-for-sale securities consist of the following at June 30, 2011 (in thousands):

| | June 30, 2011 | | | | |
|----------------------------------|----------------------|---------------------------------------|--|--|-----------------------|
| | Cost | Gross Unrealized Gains | Gross Unrealized Losses | Other-Than- Temporary Impairment Losses | Fair Value |
| Corporate notes and bonds | \$ 360,758 | \$ 474 | \$ (128) | \$ | \$ 361,104 |
| Federal agency notes and bonds | 251,136 | 769 | (8) | | 251,897 |
| Auction rate floating securities | 26,575 | | (6,691) | | 19,884 |
| Asset-backed securities | 45,011 | 38 | | | 45,049 |
| Total securities | \$ 683,480 | \$ 1,281 | \$ (6,827) | \$ | \$ 677,934 |

During the three and six months ended June 30, 2011, there were no significant gross realized gains and losses on sales of available-for-sale securities. Gross unrealized gains and losses are determined based on the specific identification method. The net adjustment to unrealized losses during the six months ended June 30, 2011, on available-for-sale securities included in stockholders' equity totaled \$0.2 million. The amortized cost and estimated fair value of the available-for-sale securities at June 30, 2011, by maturity, are shown below (in thousands):

| | June 30, 2011 | |
|---------------------------------------|----------------------|---------------------------------|
| | Cost | Estimated Fair Value |
| Available-for-sale | | |
| Due in one year or less | \$ 327,303 | \$ 327,965 |
| Due after one year through five years | 329,602 | 330,085 |

| | | |
|--------------------|------------|------------|
| Due after 10 years | 26,575 | 19,884 |
| | \$ 683,480 | \$ 677,934 |

Table of Contents

Expected maturities will differ from contractual maturities because the issuers of the securities may have the right to prepay obligations without prepayment penalties, and the Company views its available-for-sale securities as available for current operations. At June 30, 2011, approximately \$22.4 million in estimated fair value expected to mature greater than one year has been classified as long-term investments since these investments are in an unrealized loss position, and management has both the ability and intent to hold these investments until recovery of fair value, which may be maturity.

As of June 30, 2011, the Company's investments included auction rate floating securities with a fair value of \$19.9 million. The Company's auction rate floating securities are debt instruments with a long-term maturity and with an interest rate that is reset in short intervals through auctions. The negative conditions in the credit markets from 2008 through the first half of 2011 have prevented some investors from liquidating their holdings, including their holdings of auction rate floating securities. During the three months ended March 31, 2008, the Company was informed that there was insufficient demand at auction for the auction rate floating securities. As a result, these affected auction rate floating securities are now considered illiquid, and the Company could be required to hold them until they are redeemed by the holder at maturity. The Company may not be able to liquidate the securities until a future auction on these investments is successful.

During the three months ended March 31, 2010, the Company became aware of new circumstances that directly impacted the valuation of an asset-backed security that is owned by the Company. An unrealized loss on the asset-backed security, based on the Company's intent to hold the security until recovery of the fair value, had previously been recorded in stockholders' equity. Based on the new circumstances related to the investment, the Company determined that the impairment of the asset-backed security was other-than-temporary, as the Company believed it would not recover its investment even if the asset were held to maturity. A \$0.3 million impairment charge was therefore recorded in other expense, net, during the three months ended March 31, 2010 related to the asset-backed security. The asset-backed security was sold in April 2010.

The following table shows the gross unrealized losses and the fair value of the Company's investments, with unrealized losses that are not deemed to be other-than-temporarily impaired aggregated by investment category and length of time that individual securities have been in a continuous unrealized loss position at June 30, 2011 (in thousands):

| | Less Than 12 Months | | Greater Than 12 Months | |
|----------------------------------|----------------------------|-------------------|-------------------------------|-------------------|
| | Fair | Gross | Fair | Gross |
| | Value | Unrealized | Value | Unrealized |
| | | Loss | | Loss |
| Corporate notes and bonds | \$ 79,304 | \$ 128 | \$ | \$ |
| Federal agency notes and bonds | 18,892 | 8 | | |
| Auction rate floating securities | | | 19,884 | 6,691 |
| Asset-backed securities | 1,790 | | | |
| Total securities | \$ 99,986 | \$ 136 | \$ 19,884 | \$ 6,691 |

As of June 30, 2011, the Company has concluded that the unrealized losses on its investment securities are temporary in nature and are caused by changes in credit spreads and liquidity issues in the marketplace. Available-for-sale securities are reviewed quarterly for possible other-than-temporary impairment. This review includes an analysis of the facts and circumstances of each individual investment such as the severity of loss, the length of time the fair value has been below cost, the expectation for that security's performance and the creditworthiness of the issuer. Additionally, the Company does not intend to sell and it is not more-likely-than-not that the Company will be required to sell any of the securities before the recovery of their amortized cost basis.

6. FAIR VALUE MEASUREMENTS

As of June 30, 2011, the Company held certain assets that are required to be measured at fair value on a recurring basis. These included certain of the Company's short-term and long-term investments, including investments in auction rate floating securities.

Table of Contents

The Company has invested in auction rate floating securities, which are classified as available-for-sale securities and reflected at fair value. Due to events in credit markets, the auction events for some of these instruments held by the Company failed during the three months ended March 31, 2008 (see Note 5). Therefore, the fair values of these auction rate floating securities, which are primarily rated AAA, are estimated utilizing a discounted cash flow analysis as of June 30, 2011. These analyses consider, among other items, the collateralization underlying the security investments, the creditworthiness of the counterparty, the timing of expected future cash flows, and the expectation of the next time the security is expected to have a successful auction. These investments were also compared, when possible, to other observable market data with similar characteristics to the securities held by the Company. Changes to these assumptions in future periods could result in additional declines in fair value of the auction rate floating securities.

The Company's assets measured at fair value on a recurring basis subject to the disclosure requirements of ASC 820, *Fair Value Measurements and Disclosures*, at June 30, 2011, were as follows (in thousands):

| | June 30, 2011 | Fair Value Measurement at Reporting Date | | |
|-------------------------------------|------------------|---|---|--|
| | | Quoted Prices in Active Markets (Level 1) | Using Significant Other Observable Inputs (Level 2) | Significant Unobservable Inputs (Level 3) |
| Corporate notes and bonds | \$ 361,104 | \$ 361,104 | \$ | \$ |
| Federal agency notes and bonds | 251,897 | 251,897 | | |
| Auction rate floating securities | 19,884 | | | 19,884 |
| Asset-backed securities | 45,049 | 45,049 | | |
| Total assets measured at fair value | \$ 677,934 | \$ 658,050 | \$ | \$ 19,884 |

Table of Contents

The following tables present the Company's assets measured at fair value on a recurring basis using significant unobservable inputs (Level 3) for the three and six months ended June 30, 2011 (in thousands):

| | Fair Value Measurements Using Significant Unobservable Inputs (Level 3) Auction Rate Floating Securities |
|--|--|
| Balance at March 31, 2011 | \$ 20,772 |
| Transfers to (from) Level 3 | |
| Total gains (losses) included in other (income) expense, net | |
| Total gains included in other comprehensive income | 12 |
| Purchases | |
| Settlements | (900) |
| Balance at June 30, 2011 | \$ 19,884 |

| | Fair Value Measurements Using Significant Unobservable Inputs (Level 3) Auction Rate Floating Securities |
|--|--|
| Balance at December 31, 2010 | \$ 21,480 |
| Transfers to (from) Level 3 | |
| Total gains (losses) included in other (income) expense, net | |
| Total gains included in other comprehensive income | 404 |
| Purchases | |
| Settlements | (2,000) |
| Balance at June 30, 2011 | \$ 19,884 |

7. RESEARCH AND DEVELOPMENT

All research and development costs, including payments related to products under development and research consulting agreements, are expensed as incurred. The Company may continue to make non-refundable payments to third parties for new technologies and for research and development work that has been completed. These payments may be expensed at the time of payment depending on the nature of the payment made.

The Company's policy on accounting for costs of strategic collaborations determines the timing of the recognition of certain development costs. In addition, this policy determines whether the cost is classified as

development expense or capitalized as an asset. Management is required to form judgments with respect to the commercial status of such products in determining whether development costs meet the criteria for immediate expense or capitalization. For example, when the Company acquires certain products for which there is already an

Table of Contents

Abbreviated New Drug Application (ANDA) or a New Drug Application (NDA) approval related directly to the product, and there is net realizable value based on projected sales for these products, the Company capitalizes the amount paid as an intangible asset. If the Company acquires product rights which are in the development phase and to which the Company has no assurance that the third party will successfully complete its development milestones, the Company expenses such payments.

Research and development expense for the three and six months ended June 30, 2011 and 2010 are as follows (in thousands):

| | Three Months Ended | | Six Months Ended | |
|--|--------------------|------------------|------------------|------------------|
| | June 30, 2011 | June 30, 2010 | June 30, 2011 | June 30, 2010 |
| Ongoing research and development costs | \$ 7,080 | \$ 7,376 | \$ 13,948 | \$ 13,879 |
| Payments related to strategic collaborations | 7,500 | | 14,500 | |
| Share-based compensation expense | 615 | 44 | 1,020 | 100 |
| Total research and development | \$ 15,195 | \$ 7,420 | \$ 29,468 | \$ 13,979 |

8. STRATEGIC COLLABORATIONS*Collaboration with a privately-held U.S. biotechnology company*

On September 10, 2010, the Company and a privately-held U.S. biotechnology company entered into a sublicense and development agreement to develop an agent for specific dermatological conditions in the Americas and Europe and a purchase option to acquire the privately-held U.S. biotechnology company.

Under the terms of the agreements, the Company paid the privately-held U.S. biotechnology company \$5.0 million in connection with the execution of the agreement, and will pay additional potential milestone payments totaling approximately \$100.5 million upon successful completion of certain clinical, regulatory and commercial milestones.

During the three months ended December 31, 2010 and June 30, 2011, development milestones were achieved, and the Company made a \$10.0 million and a \$5.5 million payment, respectively, pursuant to the agreements. The initial \$5.0 million payment, the \$10.0 million milestone payment and the \$5.5 million milestone payment were recognized as research and development expense during the three months ended September 30, 2010, December 31, 2010 and June 30, 2011, respectively.

Anacor

On February 9, 2011, the Company entered into a research and development agreement with Anacor Pharmaceuticals, Inc. (Anacor) for the discovery and development of boron-based small molecule compounds directed against a target for the potential treatment of acne. Under the terms of the agreement, the Company paid Anacor \$7.0 million in connection with the execution of the agreement, and will pay up to \$153.0 million upon the achievement of certain research, development, regulatory and commercial milestones, as well as royalties on sales by the Company. Anacor will be responsible for discovering and conducting the early development of product candidates which utilize Anacor's proprietary boron chemistry platform, while the Company will have an option to obtain an exclusive license for products covered by the agreement. The initial \$7.0 million payment was recognized as research and development expense during the three months ended March 31, 2011.

9. SEGMENT AND PRODUCT INFORMATION

The Company operates in one business segment: pharmaceuticals. The Company's current pharmaceutical franchises are divided between the dermatological and non-dermatological fields. The dermatological field represents products for the treatment of acne and acne-related dermatological conditions and non-acne dermatological conditions. The non-dermatological field represents products for the treatment of urea cycle disorder and contract revenue. The acne and acne-related dermatological product lines include SOLODYN® and ZIANA®. During early 2011, the Company discontinued its TRIAZ® branded products and decided to no longer promote its PLEXION® branded

products. The non-acne dermatological product lines include DYSPORT®, LOPROX®,

Table of Contents

PERLANE®, RESTYLANE® and VANOS®. The non-dermatological product lines include AMMONUL® and BUPHENYL®. The non-dermatological field also includes contract revenues associated with licensing agreements and authorized generics.

The Company's pharmaceutical products, with the exception of AMMONUL® and BUPHENYL®, are promoted to dermatologists and plastic surgeons. Such products are often prescribed by physicians outside these two specialties, including family practitioners, general practitioners, primary-care physicians and OB/GYNs, as well as hospitals, government agencies, and others. Currently, the Company's products are sold primarily to wholesalers and retail chain drug stores.

Net revenues and the percentage of net revenues for each of the product categories are as follows (amounts in thousands):

| | Three Months Ended | | Six Months Ended | |
|---|--------------------|------------------|------------------|------------------|
| | June 30, 2011 | June 30, 2010 | June 30, 2011 | June 30, 2010 |
| Acne and acne-related dermatological products | \$ 123,130 | \$ 124,763 | \$ 226,592 | \$ 244,976 |
| Non-acne dermatological products | 57,719 | 41,017 | 109,940 | 75,269 |
| Non-dermatological products | 9,978 | 7,816 | 19,208 | 18,893 |
| Total net revenues | \$ 190,827 | \$ 173,596 | \$ 355,740 | \$ 339,138 |

| | Three Months Ended | | Six Months Ended | |
|---|---------------------|------------------|---------------------|------------------|
| | June 30, 2011 | June 30, 2010 | June 30, 2011 | June 30, 2010 |
| Acne and acne-related dermatological products | 65% | 72% | 64% | 72% |
| Non-acne dermatological products | 30 | 24 | 31 | 22 |
| Non-dermatological products | 5 | 4 | 5 | 6 |
| Total net revenues | 100% | 100% | 100% | 100% |

10. INVENTORIES

The Company primarily utilizes third parties to manufacture and package inventories held for sale, takes title to certain inventories once manufactured, and warehouses such goods until packaged for final distribution and sale. Inventories consist of salable products held at the Company's warehouses, as well as raw materials and components at the manufacturers' facilities, and are valued at the lower of cost or market using the first-in, first-out method. The Company provides valuation reserves for estimated obsolescence or unmarketable inventory in an amount equal to the difference between the cost of inventory and the estimated market value based upon assumptions about future demand and market conditions.

Inventory costs associated with products that have not yet received regulatory approval are capitalized if, in the view of the Company's management, there is probable future commercial use and future economic benefit. If future commercial use and future economic benefit are not considered probable, then costs associated with pre-launch inventory that has not yet received regulatory approval are expensed as research and development expense during the period the costs are incurred. As of June 30, 2011 and December 31, 2010, there were no costs capitalized into inventory for products that had not yet received regulatory approval.

Table of Contents

Inventories are as follows (in thousands):

| | June 30, 2011 | December 31, 2010 |
|-------------------|--------------------------|------------------------------|
| Raw materials | \$ 12,103 | \$ 15,801 |
| Work-in-process | 3,370 | 3,236 |
| Finished goods | 19,930 | 24,838 |
| Valuation reserve | (4,574) | (8,593) |
| Total inventories | \$ 30,829 | \$ 35,282 |

11. OTHER CURRENT LIABILITIES

Other current liabilities are as follows (in thousands):

| | June 30, 2011 | December 31, 2010 |
|--|--------------------------|------------------------------|
| Accrued incentives, including SARs liability | \$ 33,346 | \$ 33,923 |
| Deferred revenue | 13,799 | 16,422 |
| Other accrued expenses | 26,619 | 24,883 |
| | \$ 73,764 | \$ 75,228 |

Deferred revenue is comprised of the following (in thousands):

| | June 30, 2011 | December 31, 2010 |
|---|--------------------------|------------------------------|
| Deferred revenue aesthetics products, net of cost of revenue | \$ 9,802 | \$ 10,334 |
| Deferred contract revenue | 1,467 | 3,014 |
| Deferred revenue sales into distribution channel in excess of eight weeks of projected demand | 2,441 | 582 |
| Other deferred revenue | 89 | 2,492 |
| | \$ 13,799 | \$ 16,422 |

The Company defers revenue, and the related cost of revenue, of its aesthetics products, including DYSPOUR[®], PERLANE[®] and RESTYLANE[®], until its exclusive U.S. distributor ships the product to physicians. Deferred contract revenue primarily relates to the Company's strategic collaboration with Hyperion Therapeutics, Inc. The Company also defers the recognition of revenue for certain sales of inventory into the distribution channel that are in excess of eight (8) weeks of projected demand.

12. CONTINGENT CONVERTIBLE SENIOR NOTES

In June 2002, the Company sold \$400.0 million aggregate principal amount of its 2.5% Contingent Convertible Senior Notes Due 2032 (the "Old Notes") in private transactions. As discussed below, approximately \$230.8 million in principal amount of the Old Notes was exchanged for New Notes on August 14, 2003. The Old Notes bear interest at a rate of 2.5% per annum, which is payable on June 4 and December 4 of each year, beginning on December 4, 2002. The Company also agreed to pay contingent interest at a rate equal to 0.5% per annum during any six-month period, with the initial six-month period commencing June 4, 2007, if the average trading price of the Old Notes reaches certain thresholds. Contingent interest of \$0.1 million was payable at June 30, 2011. No contingent interest related to the Old Notes was payable at December 31, 2010. The Old Notes will mature on June 4, 2032.

The Company may redeem some or all of the Old Notes at any time on or after June 11, 2007, at a redemption price, payable in cash, of 100% of the principal amount of the Old Notes, plus accrued and unpaid

Table of Contents

interest, including contingent interest, if any. Holders of the Old Notes may require the Company to repurchase all or a portion of their Old Notes on June 4, 2012 and June 4, 2017, or upon a change in control, as defined in the indenture governing the Old Notes, at 100% of the principal amount of the Old Notes, plus accrued and unpaid interest to the date of the repurchase, payable in cash. Under GAAP, if an obligation is due on demand or will be due on demand within one year from the balance sheet date, even though liquidation may not be expected within that period, it should be classified as a current liability. Accordingly, the outstanding balance of Old Notes along with the deferred tax liability associated with accelerated interest deductions on the Old Notes will be classified as a current liability during the respective twelve month periods prior to June 4, 2012 and June 4, 2017. As of June 30, 2011, \$169.1 million of the Old Notes and \$57.9 million of deferred tax liabilities were classified as current liabilities in the Company's condensed consolidated balance sheets. The \$57.9 million of deferred tax liabilities were included within current deferred tax assets, net. If all of the Old Notes are put back to the Company on June 4, 2012, the Company would be required to pay \$169.1 million in outstanding principal, plus accrued interest. The Company would also be required to pay the accumulated deferred tax liability related to the Old Notes.

The Old Notes are convertible, at the holders' option, prior to the maturity date into shares of the Company's Class A common stock in the following circumstances:

- during any quarter commencing after June 30, 2002, if the closing price of the Company's Class A common stock over a specified number of trading days during the previous quarter, including the last trading day of such quarter, is more than 110% of the conversion price of the Old Notes, or \$31.96. The Old Notes are initially convertible at a conversion price of \$29.05 per share, which is equal to a conversion rate of approximately 34.4234 shares per \$1,000 principal amount of Old Notes, subject to adjustment;
- if the Company has called the Old Notes for redemption;
- during the five trading day period immediately following any nine consecutive day trading period in which the trading price of the Old Notes per \$1,000 principal amount for each day of such period was less than 95% of the product of the closing sale price of the Company's Class A common stock on that day multiplied by the number of shares of the Company's Class A common stock issuable upon conversion of \$1,000 principal amount of the Old Notes; or
- upon the occurrence of specified corporate transactions.

The Old Notes, which are unsecured, do not contain any restrictions on the payment of dividends, the incurrence of additional indebtedness or the repurchase of the Company's securities and do not contain any financial covenants.

The Company incurred \$12.6 million of fees and other origination costs related to the issuance of the Old Notes. The Company amortized these costs over the first five-year Put period, which ran through June 4, 2007.

On August 14, 2003, the Company exchanged approximately \$230.8 million in principal amount of its Old Notes for approximately \$283.9 million in principal amount of its 1.5% Contingent Convertible Senior Notes Due 2033 (the "New Notes"). Holders of Old Notes that accepted the Company's exchange offer received \$1,230 in principal amount of New Notes for each \$1,000 in principal amount of Old Notes. The terms of the New Notes are similar to the terms of the Old Notes, but have a different interest rate, conversion rate and maturity date. Holders of Old Notes that chose not to exchange continue to be subject to the terms of the Old Notes.

The New Notes bear interest at a rate of 1.5% per annum, which is payable on June 4 and December 4 of each year, beginning December 4, 2003. The Company will also pay contingent interest at a rate of 0.5% per annum during any six-month period, with the initial six-month period commencing June 4, 2008, if the average trading price of the New Notes reaches certain thresholds. No contingent interest related to the New Notes was payable at June 30, 2011 or December 31, 2010. The New Notes mature on June 4, 2033.

As a result of the exchange, the outstanding principal amounts of the Old Notes and the New Notes were \$169.2 million and \$283.9 million, respectively. The Company incurred approximately \$5.1 million of fees and other origination costs related to the issuance of the New Notes. The Company amortized these costs over the first five-year Put period, which ran through June 4, 2008.

Table of Contents

Holders of the New Notes were able to require the Company to repurchase all or a portion of their New Notes on June 4, 2008, at 100% of the principal amount of the New Notes, plus accrued and unpaid interest, including contingent interest, if any, to the date of the repurchase, payable in cash. Holders of approximately \$283.7 million of New Notes elected to require the Company to repurchase their New Notes on June 4, 2008. The Company paid \$283.7 million, plus accrued and unpaid interest of approximately \$2.2 million, to the holders of New Notes that elected to require the Company to repurchase their New Notes. The Company was also required to pay an accumulated deferred tax liability of approximately \$34.9 million related to the repurchased New Notes. This \$34.9 million deferred tax liability was paid during the second half of 2008. Following the repurchase of these New Notes, \$181,000 of principal amount of New Notes remained outstanding as of June 30, 2011 and December 31, 2010.

The remaining New Notes are convertible, at the holders' option, prior to the maturity date into shares of the Company's Class A common stock in the following circumstances:

during any quarter commencing after September 30, 2003, if the closing price of the Company's Class A common stock over a specified number of trading days during the previous quarter, including the last trading day of such quarter, is more than 120% of the conversion price of the New Notes, or \$46.51. The Notes are initially convertible at a conversion price of \$38.76 per share, which is equal to a conversion rate of approximately 25.7998 shares per \$1,000 principal amount of New Notes, subject to adjustment;

if the Company has called the New Notes for redemption;

during the five trading day period immediately following any nine consecutive day trading period in which the trading price of the New Notes per \$1,000 principal amount for each day of such period was less than 95% of the product of the closing sale price of the Company's Class A common stock on that day multiplied by the number of shares of the Company's Class A common stock issuable upon conversion of \$1,000 principal amount of the New Notes; or

upon the occurrence of specified corporate transactions.

The remaining New Notes, which are unsecured, do not contain any restrictions on the incurrence of additional indebtedness or the repurchase of the Company's securities and do not contain any financial covenants. The New Notes require an adjustment to the conversion price if the cumulative aggregate of all current and prior dividend increases above \$0.025 per share would result in at least a one percent (1%) increase in the conversion price. This threshold has not been reached and no adjustment to the conversion price has been made.

During the quarter ended June 30, 2011, the Old Notes met the criteria for the right of conversion into shares of the Company's Class A common stock. This right of conversion of the holders of Old Notes was triggered by the stock closing above \$31.96 on 20 of the last 30 trading days and the last trading day of the quarter ended June 30, 2011. The holders of Old Notes have this conversion right only until September 30, 2011. At the end of each future quarter, the conversion rights will be reassessed in accordance with the bond indenture agreement to determine if the conversion trigger rights have been achieved. During the quarter ended June 30, 2011, the New Notes did not meet the criteria for the right of conversion.

13. INCOME TAXES

Income taxes are determined using an annual effective tax rate, which generally differs from the U.S. Federal statutory rate, primarily because of state and local income taxes, enhanced charitable contribution deductions for inventory, tax credits available in the U.S., the treatment of certain share-based payments that are not designed to normally result in tax deductions, various expenses that are not deductible for tax purposes, changes in valuation allowances against deferred tax assets and differences in tax rates in certain non-U.S. jurisdictions. The Company's effective tax rate may be subject to fluctuations during the year as new information is obtained which may affect the assumptions it uses to estimate its annual effective tax rate, including factors such as its mix of pre-tax earnings in the various tax jurisdictions in which it operates, changes in valuation allowances against deferred tax assets, reserves for tax audit issues and settlements, utilization of tax credits and changes in tax laws in jurisdictions where the Company conducts operations. The Company recognizes tax benefits only if the tax position is more likely than not of being sustained. The Company recognizes deferred tax assets and liabilities for temporary differences between the financial reporting basis and the tax basis of its assets and liabilities, along with net

Table of Contents

operating losses and credit carryforwards. The Company records valuation allowances against its deferred tax assets to reduce the net carrying value to amounts that management believes is more likely than not to be realized.

At June 30, 2011, the Company has an unrealized tax loss of \$21.0 million related to the Company's option to acquire Revance or license Revance's topical product that is under development. The Company will not be able to determine the character of the loss until the Company exercises or fails to exercise its option. A realized loss characterized as a capital loss can only be utilized to offset capital gains. At June 30, 2011, the Company has recorded a valuation allowance of \$7.6 million against the deferred tax asset associated with this unrealized tax loss in order to reduce the carrying value of the deferred tax asset to \$0, which is the amount that management believes is more likely than not to be realized.

At June 30, 2011, the Company has an unrealized tax loss of \$21.9 million related to the Company's option to acquire a privately-held U.S. biotechnology company. If the Company fails to exercise its option, a capital loss will be recognized. A loss characterized as a capital loss can only be used to offset capital gains. At June 30, 2011, the Company has recorded a valuation allowance of \$7.9 million against the deferred tax asset associated with this unrealized tax loss in order to reduce the carrying value of the deferred tax asset to \$0, which is the amount that management believes is more likely than not to be realized.

During the three months ended June 30, 2011 and June 30, 2010, the Company made net tax payments of \$32.0 million and \$30.9 million, respectively. During the six months ended June 30, 2011 and June 30, 2010, the Company made net tax payments of \$38.0 million and \$47.7 million, respectively.

The Company operates in multiple tax jurisdictions and is periodically subject to audit in these jurisdictions. These audits can involve complex issues that may require an extended period of time to resolve and may cover multiple years. The Company and its domestic subsidiaries file a consolidated U.S. federal income tax return. Such returns have either been audited or settled through statute expiration through 2006. The state of California conducted an examination on the Company's tax returns for the periods ending June 30, 2005, December 31, 2005, December 31, 2006 and December 31, 2007. During the three months ended March 31, 2011, the Company reached a settlement for all periods with the state of California and paid approximately \$0.5 million. The state of California has also notified the Company of an upcoming examination of the Company's tax returns for the periods ending December 31, 2008 and December 31, 2009.

The Company owns two subsidiaries that file corporate tax returns in Sweden. The Swedish tax authorities examined the tax return of one of the subsidiaries for fiscal 2004. The examiners issued a no change letter, and the examination is complete. The Company's other subsidiary in Sweden has not been examined by the Swedish tax authorities. The Swedish statute of limitations may be open for up to five years from the date the tax return was filed. Thus, all returns filed for periods ending December 31, 2006 forward are open under the statute of limitations.

At June 30, 2011 and December 31, 2010, the Company had unrecognized tax benefits of \$1.0 million and \$1.4 million, respectively. The amount of unrecognized tax benefits which, if ultimately recognized, could favorably affect the Company's effective tax rate in a future period is \$0.6 million and \$0.9 million as of June 30, 2011 and December 31, 2010, respectively. During the next twelve months, the Company estimates that it is reasonably possible that the amount of unrecognized tax benefits will decrease by \$0.7 million.

The Company recognizes accrued interest and penalties, if applicable, related to unrecognized tax benefits in income tax expense. The Company had approximately \$0.5 million for the payment of interest and penalties accrued (net of tax benefit) at June 30, 2011 and December 31, 2010.

14. DIVIDENDS DECLARED ON COMMON STOCK

On June 8, 2011, the Company announced that its Board of Directors had declared a cash dividend of \$0.08 per issued and outstanding share of the Company's Class A common stock, which was paid on July 29, 2011, to stockholders of record at the close of business on July 1, 2011. The \$5.1 million dividend was recorded as a reduction of accumulated earnings and is included in other current liabilities in the accompanying condensed consolidated balance sheets as of June 30, 2011. The Company has not adopted a dividend policy.

Table of Contents

15. COMPREHENSIVE INCOME

Total comprehensive income includes net income and other comprehensive income (loss), which consists of foreign currency translation adjustments, unrealized gains and losses on available-for-sale investments and unamortized prior service costs related to the Company's supplemental executive retirement plan. Total comprehensive income for the three months ended June 30, 2011 and 2010, was \$7.4 million and \$36.9 million, respectively. Total comprehensive income for the six months ended June 30, 2011 and 2010, was \$27.0 million and \$72.9 million, respectively. Included as a reduction of total comprehensive income for the three and six months ended June 30, 2011 is \$21.4 million related to the establishment of prior service costs related to the Company's supplemental executive retirement plan, net of income tax benefit.

Table of Contents**16. NET INCOME PER COMMON SHARE**

The following table sets forth the computation of basic and diluted net income per common share (in thousands, except per share amounts):

| | June 30, 2011 | | Three Months Ended | | June 30, 2010 | |
|---|-----------------------|-------------------------|--------------------|-----------------------|-------------------------|------------|
| | Continuing Operations | Discontinued Operations | Net Income | Continuing Operations | Discontinued Operations | Net Income |
| BASIC | | | | | | |
| Net income (loss) | \$ 34,512 | \$ (5,729) | \$ 28,783 | \$ 40,928 | \$ (4,428) | \$ 36,500 |
| Less: income (loss) allocated to participating securities | 1,113 | | 916 | 1,355 | | 1,206 |
| Net income (loss) available to common stockholders | 33,399 | (5,729) | 27,867 | 39,573 | (4,428) | 35,294 |
| Weighted average number of common shares outstanding | 60,308 | 60,308 | 60,308 | 58,271 | 58,271 | 58,271 |
| Basic net income (loss) per common share | \$ 0.55 | \$ (0.09) | \$ 0.46 | \$ 0.68 | \$ (0.08) | \$ 0.61 |
| DILUTED | | | | | | |
| Net income (loss) | \$ 34,512 | \$ (5,729) | \$ 28,783 | \$ 40,928 | \$ (4,428) | \$ 36,500 |
| Less: income (loss) allocated to participating securities | 1,113 | | 916 | 1,355 | | 1,206 |
| Net income (loss) available to common stockholders | 33,399 | (5,729) | 27,867 | 39,573 | (4,428) | 35,294 |
| Less: Undistributed earnings allocated to unvested stockholders | (987) | | (796) | (1,263) | | (1,113) |
| Add: Undistributed earnings re-allocated to unvested stockholders | 971 | | 783 | 1,256 | | 1,107 |
| Add: Tax-effected interest expense related to Old Notes | 711 | | 711 | 666 | | 666 |
| | \$ 34,094 | \$ (5,729) | \$ 28,565 | \$ 40,232 | \$ (4,428) | \$ 35,954 |

Net income
(loss) assuming dilution

Weighted average number
of common shares
outstanding

| | | | | | |
|--------|--------|--------|--------|--------|--------|
| 60,308 | 60,308 | 60,308 | 58,271 | 58,271 | 58,271 |
|--------|--------|--------|--------|--------|--------|

Effect of dilutive
securities:

| | | | | | | |
|-----------|-------|--|-------|-------|--|-------|
| Old Notes | 5,823 | | 5,823 | 5,823 | | 5,823 |
|-----------|-------|--|-------|-------|--|-------|

| | | | | | | |
|-----------|---|--|---|---|--|---|
| New Notes | 4 | | 4 | 4 | | 4 |
|-----------|---|--|---|---|--|---|

| | | | | | | |
|---------------|-------|--|-------|-----|--|-----|
| Stock options | 1,005 | | 1,005 | 297 | | 297 |
|---------------|-------|--|-------|-----|--|-----|

Weighted average number
of common shares
assuming dilution

| | | | | | |
|--------|--------|--------|--------|--------|--------|
| 67,140 | 60,308 | 67,140 | 64,395 | 58,271 | 64,395 |
|--------|--------|--------|--------|--------|--------|

Diluted net income

| | | | | | | |
|-------------------------|---------|-----------|---------|---------|-----------|---------|
| (loss) per common share | \$ 0.51 | \$ (0.09) | \$ 0.43 | \$ 0.62 | \$ (0.08) | \$ 0.56 |
|-------------------------|---------|-----------|---------|---------|-----------|---------|

Table of Contents

| | Six Months Ended | | | | | |
|--|----------------------------------|--|-----------------------|----------------------------------|--|-----------------------|
| | Continuing Operations | June 30, 2011 Discontinued Operations | Net Income | Continuing Operations | June 30, 2010 Discontinued Operations | Net Income |
| BASIC | | | | | | |
| Net income (loss) | \$ 61,197 | \$ (13,054) | \$ 48,143 | \$ 80,946 | \$ (9,078) | \$ 71,868 |
| Less: income (loss) allocated to participating securities | 1,905 | | 1,469 | 2,673 | | 2,368 |
| Net income (loss) available to common stockholders | 59,292 | (13,054) | 46,674 | 78,273 | (9,078) | 69,500 |
| Weighted average number of common shares outstanding | 59,719 | 59,719 | 59,719 | 58,161 | 58,161 | 58,161 |
| Basic net income (loss) per common share | \$ 0.99 | \$ (0.22) | \$ 0.78 | \$ 1.35 | \$ (0.16) | \$ 1.19 |
| DILUTED | | | | | | |
| Net income (loss) | \$ 61,197 | \$ (13,054) | \$ 48,143 | \$ 80,946 | \$ (9,078) | \$ 71,868 |
| Less: income (loss) allocated to participating securities | 1,905 | | 1,469 | 2,673 | | 2,368 |
| Net income (loss) available to common stockholders | 59,292 | (13,054) | 46,674 | 78,273 | (9,078) | 69,500 |
| Less: Undistributed earnings allocated to unvested stockholders | (1,668) | | (1,245) | (2,474) | | (2,170) |
| Add: Undistributed earnings re-allocated to unvested stockholders | 1,647 | | 1,229 | 2,461 | | 2,159 |
| Add: Tax-effected interest expense related to Old Notes | 1,376 | | 1,376 | 1,332 | | 1,332 |
| Add: Tax-effected interest expense related to New Notes | 1 | | 1 | 1 | | 1 |
| | \$ 60,648 | \$ (13,054) | \$ 48,035 | \$ 79,593 | \$ (9,078) | \$ 70,822 |

Net income
(loss) assuming dilution

Weighted average number
of common shares
outstanding

| | | | | | |
|--------|--------|--------|--------|--------|--------|
| 59,719 | 59,719 | 59,719 | 58,161 | 58,161 | 58,161 |
|--------|--------|--------|--------|--------|--------|

Effect of dilutive
securities:

| | | | | | |
|-----------|-------|-------|-------|-------|-------|
| Old Notes | 5,823 | 5,823 | 5,823 | 5,823 | 5,823 |
|-----------|-------|-------|-------|-------|-------|

| | | | | | |
|-----------|---|---|---|---|---|
| New Notes | 4 | 4 | 4 | 4 | 4 |
|-----------|---|---|---|---|---|

| | | | | | |
|---------------|-----|-----|-----|-----|-----|
| Stock options | 801 | 801 | 306 | 306 | 306 |
|---------------|-----|-----|-----|-----|-----|

Weighted average number
of common shares
assuming dilution

| | | | | | |
|--------|--------|--------|--------|--------|--------|
| 66,347 | 59,719 | 66,347 | 64,294 | 58,161 | 64,294 |
|--------|--------|--------|--------|--------|--------|

Diluted net income

| | | | | | | |
|-------------------------|---------|-----------|---------|---------|-----------|---------|
| (loss) per common share | \$ 0.91 | \$ (0.22) | \$ 0.72 | \$ 1.24 | \$ (0.16) | \$ 1.10 |
|-------------------------|---------|-----------|---------|---------|-----------|---------|

Diluted net income per common share must be calculated using the if-converted method. Diluted net income per share using the if-converted method is calculated by adjusting net income for tax-effected net interest on the Old Notes and New Notes, divided by the weighted average number of common shares outstanding assuming conversion.

Table of Contents

Unvested share-based payment awards that contain rights to receive nonforfeitable dividends or dividend equivalents (whether paid or unpaid) are participating securities, and thus, are included in the two-class method of computing earnings per share. The two-class method is an earnings allocation formula that treats a participating security as having rights to earnings that would otherwise have been available to common stockholders. Restricted stock granted to certain employees by the Company (see Note 3) participate in dividends on the same basis as common shares, and these dividends are not forfeitable by the holders of the restricted stock. As a result, the restricted stock grants meet the definition of a participating security.

The diluted net income per common share computation for the three months ended June 30, 2011 and 2010 excludes 1,797,876 and 8,027,204 shares of stock, respectively, that represented outstanding stock options whose impact would be anti-dilutive. The diluted net income per common share computation for the six months ended June 30, 2011 and 2010 excludes 3,291,806 and 8,559,315 shares of stock, respectively, that represented outstanding stock options whose impact would be anti-dilutive.

Due to the net loss from discontinued operations during the three and six months ended June 30, 2011 and 2010, diluted earnings per share and basic earnings per share from discontinued operations are the same, as the effect of potentially dilutive securities would be anti-dilutive.

17. COMMITMENTS AND CONTINGENCIES**Legal Matters**

The Company is currently party to various legal proceedings, including those noted in this section. Unless specifically noted below, any possible range of loss associated with the legal proceedings described below is not reasonably estimable at this time. The Company is engaged in numerous other legal actions not described below arising in the ordinary course of its business and, while there can be no assurance, the Company believes that the ultimate outcome of these actions will not have a material adverse effect on its operating results, liquidity or financial position.

From time to time the Company may conclude it is in the best interests of its stockholders, employees, and customers to settle one or more litigation matters, and any such settlement could include substantial payments; however, other than as noted below, the Company has not reached this conclusion with respect to any particular matter at this time. There are a variety of factors that influence the Company's decisions to settle and the amount the Company may choose to pay, including the strength of its case, developments in the litigation, the behavior of other interested parties, the demand on management time and the possible distraction of the Company's employees associated with the case and/or the possibility that the Company may be subject to an injunction or other equitable remedy. It is difficult to predict whether a settlement is possible, the amount of an appropriate settlement or when is the opportune time to settle a matter in light of the numerous factors that go into the settlement decision. Unless otherwise specified below, any settlement payment made pursuant to any of the completed settlement agreements described below is immaterial to the Company for financial reporting purposes.

Stockholder Class Action Litigation

On October 3, 10 and 27, 2008, purported stockholder class action lawsuits styled Andrew Hall v. Medicis Pharmaceutical Corp., et al. (Case No. 2:08-cv-01821-MHB); Steamfitters Local 449 Pension Fund v. Medicis Pharmaceutical Corp., et al. (Case No. 2:08-cv-01870-DKD); and Darlene Oliver v. Medicis Pharmaceutical Corp., et al. (Case No. 2:08-cv-01964-JAT) were filed in the United States District Court for the District of Arizona on behalf of stockholders who purchased securities of the Company during the period between October 30, 2003 and approximately September 24, 2008. The Court consolidated these actions into a single proceeding and on May 18, 2009 an amended complaint was filed alleging violations of the federal securities laws arising out of the Company's restatement of its consolidated financial statements in 2008. On December 2, 2009, the Court granted the Company's and other defendants' dismissal motions and dismissed the consolidated amended complaint without prejudice. On January 18, 2010 the lead plaintiff filed a second amended complaint, and on or about August 9, 2010, the Court denied the Company's and other defendants' related dismissal motions. On December 17, 2010, the lead plaintiff filed a motion for class certification, and the defendants filed an opposition to the motion on March 8, 2011. On June 6, 2011, the Company, certain of its current officers who are named in the complaint, and the Company's outside auditors entered into a Memorandum of Understanding (the "Class Action MOU") with the

Table of Contents

plaintiffs' representatives to memorialize an agreement in principle to settle the pending action. Under the terms of the settlement agreement, which remains subject to Court approval among other customary conditions, the Company's portion of the settlement will be paid entirely by insurance. The Company's outside auditors also will contribute to this settlement. The Company itself is not required to make any payments to fund the settlement. The settlement agreement contains no admission of liability by the Company or the named individuals in the action, the allegations of which are expressly denied in the Class Action MOU. In the event the settlement is not approved by the Court, the Company will continue to vigorously defend the claims in the class action lawsuits. There can be no assurance that the Court will approve the settlement, or that the Company will otherwise ultimately be successful in settling the lawsuits or in defending the lawsuits, and an adverse resolution of the lawsuits could have a material adverse effect on the Company's financial position and results of operations in the period in which the lawsuits are resolved.

Stockholder Derivative Lawsuits

On January 21, 2009, the Company received a letter from an alleged stockholder demanding that its Board of Directors take certain actions, including potentially legal action, in connection with the restatement of its consolidated financial statements in 2008. The letter stated that, if the Board of Directors did not take the demanded action, the alleged stockholder would commence a derivative action on behalf of the Company. The Company's Board of Directors reviewed the letter during the course of 2009 and established a special committee of the Board of Directors, comprised of directors who are independent and disinterested with respect to the allegations in the letter, to assess the allegations contained in the letter. The special committee engaged outside counsel to assist with the investigation. The special committee completed its investigation, and on or about February 16, 2010, the Board of Directors, pursuant to the report and recommendation of the special committee, resolved to decline the derivative demand. On February 26, 2010, Company counsel sent a declination letter to opposing counsel. On or about October 21, 2010, the stockholder filed a derivative complaint against the Company and its directors and certain officers in the Superior Court of the State of Arizona in and for the County of Maricopa, alleging that such individuals breached their fiduciary duties to the Company in connection with the restatement. The stockholder seeks to recover unspecified damages and costs, including counsel and expert fees.

On or about October 20, 2010, a second alleged stockholder of the Company filed a derivative complaint against the Company and its directors and certain officers in the Superior Court of the State of Arizona in and for the County of Maricopa. The complaint alleges, among other things, that such individuals breached their fiduciary duties to the Company in connection with the restatement. The complaint further alleges that a demand upon the Board of Directors to institute an action in the Company's name would be futile and that the stockholder is therefore excused under Delaware law from making such a demand prior to filing the complaint. The stockholder seeks, among other things, to recover unspecified damages and costs, including counsel and expert fees.

On June 6, 2011, the Company and certain of its current officers and directors who are named in the complaints entered into a Memorandum of Understanding (the "Derivative Lawsuits MOU") with the plaintiffs' representatives to memorialize an agreement in principle to settle the pending actions. The only financial component under the settlement agreement, which remains subject to Court approval among other customary conditions, involves payment of plaintiffs' attorneys' fees, which will be paid entirely by insurance. The Company itself is not required to make any payments to fund the settlement. The settlement also reflects certain control and other enhancements taken by the Company in connection with and subsequent to the restatement of its consolidated financial statements in 2008. The settlement agreement contains no admission of liability by the Company or the named individuals in the lawsuits, the allegations of which are expressly denied in the Derivative Lawsuits MOU. In the event the settlement is not approved by the Court, the Company will continue to vigorously defend the claims in the derivative lawsuits. There can be no assurance that the Court will approve the settlement, or that the Company will otherwise ultimately be successful in settling the lawsuits or in defending the lawsuits, and an adverse resolution of the lawsuits could have a material adverse effect on the Company's financial position and results of operations in the period in which the lawsuits are resolved.

Hyperion Arbitration

On June 23, 2011, Hyperion Therapeutics, Inc. ("Hyperion") filed a demand for arbitration before the American Arbitration Association for a judgment declaration of the rights and obligations of Hyperion and Ucycleld Pharma,

Inc., a subsidiary of the Company (Ucyclid), under a collaboration agreement between the parties, dated August 23, 2007, as amended (the Collaboration Agreement). Pursuant to the terms of the Collaboration

Table of Contents

Agreement, Hyperion is responsible for the ongoing research and development of a compound referred to as HPN-100 (formerly known as GT4P) for the treatment of urea cycle disorder, hepatic encephalopathies and other indications. In addition, if certain specified conditions are satisfied, then Hyperion will have certain purchase rights under the Collaboration Agreement with respect to HPN-100, as well as Ucyclyd's existing on-market products, AMMONU[®] and BUPHENYL[®], and will be required to pay Ucyclyd royalties and regulatory and sales milestone payments in connection with certain licenses that will be granted to Hyperion upon exercise of the purchase rights. In its demand for arbitration, Hyperion requested a judgment regarding the rights of the parties in connection with the development activities relating to HPN-100, including relating to the submission of a NDA to the FDA for HPN-100 for the treatment of urea cycle disorder. The Company responded to the demand for arbitration on July 28, 2011. In its response, the Company denied the allegations of Hyperion and requested the arbitration panel deny Hyperion's requested declaratory relief. Additionally, the Company brought counterclaims against Hyperion and sought a declaration of rights in the Company's favor and an award of damages.

In addition to the matters discussed above, in the ordinary course of business, the Company is involved in a number of legal actions, both as plaintiff and defendant, and could incur uninsured liability in any one or more of them. Although the outcome of these actions is not presently determinable, it is the opinion of the Company's management, based upon the information available at this time, that the expected outcome of these matters, individually or in the aggregate, will not have a material adverse effect on the results of operations, financial condition or cash flows of the Company.

18. RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS

In May 2011, the FASB issued Accounting Standards Update (ASU) No. 2011-04, *Amendments to Achieve Common Fair Value Measurement and Disclosure Requirements in U.S. GAAP and International Financial Reporting Standards* (Topic 820) *Fair Value Measurement*, to provide a consistent definition of fair value and ensure that the fair value measurement and disclosure requirements are similar between U.S. GAAP and International Financial Reporting Standards. ASU No. 2011-04 changes certain fair value measurement principles and enhances the disclosure requirements, particularly for level 3 fair value measurements. ASU No. 2011-04 is effective for interim and annual reporting periods beginning after December 15, 2011 and must be applied prospectively. The Company is currently assessing what impact, if any, the revised guidance will have on its results of operations and financial condition.

In June 2011, the FASB issued ASU No. 2011-05, *Comprehensive Income* (Topic 220): *Presentation of Comprehensive Income*. The updated guidance amends the FASB Accounting Standards Codification (Codification) to allow an entity the option to present the total of comprehensive income, the components of net income, and the components of other comprehensive income either in a single continuous statement of comprehensive income or in two separate but consecutive statements. In both alternatives, an entity is required to present each component of net income along with total net income, each component of other comprehensive income along with a total for other comprehensive income, and a total amount for comprehensive income. ASU No. 2011-05 eliminates the option to present the components of other comprehensive income as part of the statement of changes in stockholders' equity. The amendments to the Codification in the ASU do not change the items that must be reported in other comprehensive income or when an item of other comprehensive income must be reclassified to net income. ASU No. 2011-05 will be applied retrospectively. ASU No. 2011-05 is effective for annual reporting periods beginning after December 15, 2011, with early adoption permitted, and will be applied retrospectively. It is expected that the adoption of this amendment will only impact the presentation of comprehensive income within the Company's consolidated financial statements.

19. SUBSEQUENT EVENTS

The Company has evaluated subsequent events through the date of issuance of its financial statements.
License and Settlement Agreement with Lupin

On July 21, 2011, the Company entered into a License and Settlement Agreement (the Settlement Agreement) with Lupin Limited and Lupin Pharmaceuticals, Inc. (together, Lupin). Under the terms of the Settlement Agreement, the Company agreed to grant to Lupin a future license to make and sell its generic versions of SOLODYN[®] in 45mg, 90mg and 135mg strengths under the SOLODYN[®] intellectual property rights belonging to the Company, with the

license grant effective November 26, 2011, or earlier under certain conditions. The

Table of Contents

Company also agreed to grant to Lupin future licenses to make and sell its generic versions of SOLODYN® in 65mg and 115mg strengths effective in February 2018, or earlier under certain conditions, and its generic versions of SOLODYN® in 55mg (against which Lupin's Paragraph IV Patent Certification was the first received by the Company), 80mg and 105mg strengths effective in February 2019, or earlier under certain conditions. The Settlement Agreement provides that Lupin will be required to pay the Company royalties based on sales of Lupin's generic SOLODYN® products pursuant to the foregoing licenses.

Pursuant to the Settlement Agreement, the companies agreed to terminate all legal disputes between them relating to SOLODYN®. In addition, Lupin confirmed that the Company's patents relating to SOLODYN® are valid and enforceable, and cover Lupin's activities relating to Lupin's generic SOLODYN® products under an ANDA. Lupin also agreed to be permanently enjoined from any distribution of generic SOLODYN® products in the U.S. except as described above.

On July 21, 2011, the Company entered into a Joint Development Agreement (the "Joint Development Agreement") with Lupin Limited, on behalf of itself and its affiliates (hereinafter collectively referred to in this paragraph as "Lupin"), whereby the Company and Lupin will collaborate to develop multiple novel proprietary therapeutic products. Pursuant to the Joint Development Agreement, subject to the terms and conditions contained therein, the Company will make an up-front \$20 million payment to Lupin and will make additional payments to Lupin of up to \$38 million upon the achievement of certain research, development, regulatory and other milestones, as well as royalty payments on sales of the products covered under the agreement. In addition, the Company will receive an exclusive, worldwide (excluding India) license on the sale of the products covered under the Joint Development Agreement. The \$20 million up-front payment will be recognized as research and development expense during the three months ended September 30, 2011.

Stock Repurchase Plan

On August 8, 2011, the Company announced that its Board of Directors approved a Stock Repurchase Plan to purchase up to \$200 million in aggregate value of shares of Medicis Class A common stock. Any repurchases will be made in compliance with the Securities and Exchange Commission's Rule 10b-18.

The number of shares to be repurchased and the timing of repurchases (if any) will depend on a variety of factors, including, but not limited to, stock price, economic and market conditions and corporate and regulatory requirements. The plan does not obligate the Company to repurchase any common stock. The plan is scheduled to terminate on the earlier of the first anniversary of the plan or the time at which the purchase limit is reached, but may be suspended or terminated at any time at the Company's discretion without prior notice.

Table of Contents

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations

Executive Summary

We are a leading independent specialty pharmaceutical company focused primarily on helping patients attain a healthy and youthful appearance and self-image through the development and marketing in the U.S. of products for the treatment of dermatological and aesthetic conditions. We also market products in Canada for the treatment of dermatological and aesthetic conditions and began commercial efforts in Europe with our acquisition of LipoSonix in July 2008. We offer a broad range of products addressing various conditions or aesthetics improvements, including facial wrinkles, acne, fungal infections, hyperpigmentation, photoaging, psoriasis, seborrheic dermatitis and cosmesis (improvement in the texture and appearance of skin).

Our current product lines are divided between the dermatological and non-dermatological fields. The dermatological field represents products for the treatment of acne and acne-related dermatological conditions and non-acne dermatological conditions. The non-dermatological field represents products for the treatment of urea cycle disorder and contract revenue. Our acne and acne-related dermatological product lines include SOLODYN® and ZIANA®. During early 2011, we discontinued our TRIAZ® branded products and decided to no longer promote our PLEXION® branded products. Our non-acne dermatological product lines include DYSPORT®, LOPROX®, PERLANE®, RESTYLANE® and VANOS®. Our non-dermatological product lines include AMMONUL® and BUPHENYL®. Our non-dermatological field also includes contract revenues associated with licensing agreements and authorized generic agreements.

Financial Information About Segments

We operate in one business segment: pharmaceuticals. Our current pharmaceutical franchises are divided between the dermatological and non-dermatological fields. Information on revenues, operating income, identifiable assets and supplemental revenue of our business franchises appears in the condensed consolidated financial statements included in Item 1 hereof.

Key Aspects of Our Business

We derive a majority of our revenue from our primary products: DYSPORT®, PERLANE®, RESTYLANE®, SOLODYN®, VANOS® and ZIANA®. We believe that sales of our primary products will constitute a significant portion of our revenue for 2011.

We have built our business by executing a four-part growth strategy: promoting existing brands, developing new products and important product line extensions, entering into strategic collaborations and acquiring complementary products, technologies and businesses. Our core philosophy is to cultivate high integrity relationships of trust and confidence with the foremost dermatologists and the leading plastic surgeons in the U.S. We rely on third parties to manufacture our products (except for the LIPOSONIX™ system).

We estimate customer demand for our prescription products primarily through use of third party syndicated data sources which track prescriptions written by health care providers and dispensed by licensed pharmacies. The data represents extrapolations from information provided only by certain pharmacies and are estimates of historical demand levels. We estimate customer demand for our non-prescription products primarily through internal data that we compile. We observe trends from these data and, coupled with certain proprietary information, prepare demand forecasts that are the basis for purchase orders for finished and component inventory from our third party manufacturers and suppliers. Our forecasts may fail to accurately anticipate ultimate customer demand for our products. Overestimates of demand and sudden changes in market conditions may result in excessive inventory production and underestimates may result in inadequate supply of our products in channels of distribution.

We schedule our inventory purchases to meet anticipated customer demand. As a result, miscalculation of customer demand or relatively small delays in our receipt of manufactured products could result in revenues being deferred or lost. Our operating expenses are based upon anticipated sales levels, and a high percentage of our operating expenses are relatively fixed in the short term.

We sell our products primarily to major wholesalers and retail pharmacy chains. Approximately 75-80% of our gross revenues are typically derived from two major drug wholesale concerns. Depending on the customer, we recognize revenue at the time of shipment to the customer, or at the time of receipt by the customer, net of estimated

Table of Contents

provisions. We recognize revenue on our aesthetics products DYSPO[®], PERLANE[®] and RESTYLANE[®] upon shipment from McKesson, our exclusive U.S. distributor of these products, to physicians. Consequently, variations in the timing of revenue recognition could cause significant fluctuations in operating results from period to period and may result in unanticipated periodic earnings shortfalls or losses. We have distribution services agreements with our two largest wholesale customers. We review the supply levels of our significant products sold to major wholesalers by reviewing periodic inventory reports that are supplied to us by our major wholesalers in accordance with the distribution services agreements. We rely wholly upon our wholesale and retail chain drugstore customers to effect the distribution allocation of substantially all of our prescription products. We believe our estimates of trade inventory levels of our products, based on our review of the periodic inventory reports supplied by our major wholesalers and the estimated demand for our products based on prescription and other data, are reasonable. We further believe that inventories of our products among wholesale customers, taken as a whole, are similar to those of other specialty pharmaceutical companies, and that our trade practices, which periodically involve volume discounts and early payment discounts, are typical of the industry.

We periodically offer promotions to wholesale and retail chain drugstore customers to encourage dispensing of our prescription products, consistent with prescriptions written by licensed health care providers. Because many of our prescription products compete in multi-source markets, it is important for us to ensure the licensed health care providers dispensing instructions are fulfilled with our branded products and are not substituted with a generic product or another therapeutic alternative product which may be contrary to the licensed health care providers recommended and prescribed Medicis brand. We believe that a critical component of our brand protection program is maintenance of full product availability at wholesale and drugstore customers. We believe such availability reduces the probability of local and regional product substitutions, shortages and backorders, which could result in lost sales. We expect to continue providing favorable terms to wholesale and retail chain drugstore customers as may be necessary to ensure the fullest possible distribution of our branded products within the pharmaceutical chain of commerce. From time to time we may enter into business arrangements (e.g., loans or investments) involving our customers and those arrangements may be reviewed by federal and state regulators.

Purchases by any given customer, during any given period, may be above or below actual prescription volumes of any of our products during the same period, resulting in fluctuations of product inventory in the distribution channel. In addition, we consistently assess our product mix and portfolio to promote a high level of profitability and revenues and to ensure that our products are responsive to consumer tastes and changes to regulatory classifications. During early 2011, we discontinued our TRIAZ[®] branded products and decided to no longer promote our PLEXION[®] branded products.

Recent Developments

As described in more detail below, the following significant events and transactions occurred during the six months ended June 30, 2011, and affected our results of operations, our cash flows and our financial condition:

Research and development agreement with Anacor;

Settlement Agreement with Teva;

Classification of LipoSonix as a discontinued operation;

Increase of our quarterly dividend from \$0.06 per share to \$0.08 per share;

Development milestone payment related to our collaboration with a privately-held U.S. biotechnology company;

Issuance of new patent covering SOLODYN[®];

Settlement of class action and derivative lawsuits; and

Establishment of a Supplemental Executive Retirement Plan.

Research and development agreement with Anacor

On February 9, 2011, we entered into a research and development agreement with Anacor Pharmaceuticals, Inc. (Anacor) for the discovery and development of boron-based small molecule compounds directed against a target for the potential treatment of acne. Under the terms of the agreement, we paid Anacor \$7.0 million in connection with the execution of the agreement, and will pay up to \$153.0 million upon the achievement of certain research, development, regulatory and commercial milestones, as well as royalties on sales by us. Anacor will be responsible for discovering and conducting the early development of product candidates which utilize Anacor s proprietary boron chemistry platform, while we will have an option to obtain an exclusive license for products

Table of Contents

covered by the agreement. The initial \$7.0 million payment was recognized as research and development expense during the three months ended March 31, 2011.

Settlement Agreement with Teva

On February 24, 2011, we entered into a Settlement Agreement (*Teva Settlement Agreement*) with Barr Laboratories, Inc., a subsidiary of Teva Pharmaceuticals USA, Inc., on behalf of itself and certain of its affiliates, including Teva Pharmaceuticals USA, Inc. (collectively, *Teva*). Under the terms of the *Teva Settlement Agreement*, we agreed to grant to Teva a future license to make and sell our generic versions of SOLODYN® in 65mg and 115mg strengths under the SOLODYN® intellectual property rights belonging to us, with the license grant effective in February 2018, or earlier under certain conditions. We also agreed to grant to Teva a future license to make and sell generic versions of SOLODYN® in 55mg, 80mg and 105mg strengths under our SOLODYN® intellectual property rights, with the license grant effective in February 2019, or earlier under certain conditions. The *Teva Settlement Agreement* provides that Teva will be required to pay us royalties based on sales of Teva's generic SOLODYN® products pursuant to the foregoing licenses. Pursuant to the *Teva Settlement Agreement*, the companies agreed to terminate all legal disputes between them relating to SOLODYN®. In addition, Teva confirmed that our patents relating to SOLODYN® are valid and enforceable, and cover Teva's activities relating to Teva's generic SOLODYN® products under ANDA No. 65-485 and any amendments and supplements thereto. Teva also agreed to be permanently enjoined from any distribution of generic SOLODYN® products in the U.S. except as described above. The United States District Court for the District of Maryland subsequently entered a permanent injunction against any infringement by Teva.

Classification of LipoSonix as a discontinued operation

On February 25, 2011, we announced that as a result of our strategic planning process and the current regulatory and commercial capital equipment environment, we determined to explore strategic alternatives for our LipoSonix business including, but not limited to, the sale of the stand-alone business. We have engaged Deutsche Bank to assist us in our exploration of strategic alternatives for LipoSonix. As a result of this decision, we now classify the LipoSonix business as a discontinued operation for financial statement reporting purposes.

Increase of our quarterly dividend from \$0.06 per share to \$0.08 per share

On March 22, 2011, we announced that our Board of Directors had declared a cash dividend of \$0.08 per issued and outstanding share of our Class A common stock, which was paid on April 29, 2011, to stockholders of record at the close of business on April 1, 2011. This represented a 33% increase compared to our previous \$0.06 dividend. A subsequent cash dividend announced in June 2011 was also at the rate of \$0.08 per issued and outstanding share of our Class A common stock. The dividend was paid on July 29, 2011 to stockholders of record at the close of business on July 1, 2011.

Development milestone payment related to our collaboration with a privately-held U.S. biotechnology company

On September 10, 2010, we and a privately-held U.S. biotechnology company entered into a sublicense and development agreement to develop an agent for specific dermatological conditions in the Americas and Europe and a purchase option to acquire the privately-held U.S. biotechnology company. Under the terms of the agreements, we paid the privately-held U.S. biotechnology company \$5.0 million in connection with the execution of the agreement, and will pay additional potential milestone payments totaling approximately \$100.5 million upon successful completion of certain clinical, regulatory and commercial milestones.

During the three months ended June 30, 2011, a development milestone was achieved, and we made a \$5.5 million payment pursuant to the agreements. The \$5.5 million milestone payment was recognized as research and development expense during the three months ended June 30, 2011.

Issuance of new patent covering SOLODYN®

On April 5, 2011, the United States Patent and Trademark Office (*USPTO*) issued U.S. Patent No. 7,919,483, entitled *Method For The Treatment Of Acne* (the *483 Patent*) to us. The *483 Patent*, which expires in February 2027, covers methods of using a controlled-release oral dosage form of minocycline to treat acne, including the use of our product SOLODYN® in all eight currently available dosage forms. As previously reported,

Table of Contents

the USPTO issued a Notice of Allowance for U.S. Application No. 11/166,817, the patent application for the 483 Patent, in October 2009 and a second Notice of Allowance in April 2010 following the completion of a Request for Continued Examination which we filed with the USPTO in November 2009.

Settlement of class action and derivative lawsuits

On June 6, 2011, we, certain of our current officers and directors named in the class action and derivative lawsuits more fully described under *Legal Matters* in Note 17 in the notes to the condensed consolidated financial statements, included in Part I, Item I of this Report, and our outside auditors entered into Memoranda of Understanding (the *MOUs*) with the plaintiffs' representatives to memorialize an agreement in principle to settle the class action, as well as both stockholder derivative lawsuits. Under the terms of these settlement agreements, which remain subject to approval by the applicable courts among other customary conditions, our portion of the class action settlement will be paid entirely by insurance. Our outside auditors also will contribute to this settlement. The derivative lawsuits settlement, the only financial component of which involves payment of plaintiffs' attorneys' fees, also will be paid entirely by insurance. We are not required to make any payments to fund the settlements of the class action or the derivative lawsuits. The settlement of the derivative lawsuits reflects certain control and other enhancements undertaken by us in connection with and subsequent to the restatement of our consolidated financial statements in 2008. The settlement agreements contain no admission of liability by us or the named individuals in the respective actions, the allegations of which are expressly denied in the *MOUs*.

Establishment of a Supplemental Executive Retirement Plan

On June 24, 2011, our Compensation Committee adopted the Medicis Pharmaceutical Supplemental Executive Retirement Plan (the *SERP*), a non-qualified, noncontributory, defined benefit pension plan that provides supplemental retirement income for a select group of officers, including our named executive officers. The *SERP* is effective as of June 1, 2011. Retirement benefits are based on a *SERP* participant's years of service and average earnings (base salary plus cash bonus or incentive payments) during any three calendar years of service (regardless of whether the years are consecutive), beginning with the 2009 calendar year.

A *SERP* participant vests in 1/6th of his or her retirement benefit per plan year, effective as of the first day of the plan year, and becomes fully vested in his or her accrued retirement benefit upon (1) the participant's normal retirement date, provided that the participant has at least fifteen years of service with the Company and is employed by the Company on such date, (2) the participant's separation from service due to a discharge without cause or resignation for good reason (as such terms are defined in the participant's employment agreement, or in the absence of such employment agreement or definitions, in the Company's Executive Retention Plan), or (3) a change in control of the Company. A *SERP* participant accrues his or her retirement benefit based on (x) the participant's number of years of service with the Company (including prior years of service), divided by (y) the number of years designated for such participant's tier (which ranges from five to twenty years).

Participants in the *SERP* received credit for prior service with us. The prior service accrued benefit of approximately \$33.8 million was recorded as other comprehensive income within stockholders' equity, and is amortized as compensation expense over the remaining service years of each participant. Amortization of prior service costs recognized as compensation expense during the three months ended June 30, 2011, was approximately \$0.4 million, representing one month of amortization. We also established a deferred tax asset of approximately \$12.0 million, which was also recorded as other comprehensive income.

*Subsequent Events**License and Settlement Agreement with Lupin*

On July 21, 2011, we entered into a License and Settlement Agreement (the *Settlement Agreement*) with Lupin Limited and Lupin Pharmaceuticals, Inc. (together, *Lupin*). Under the terms of the *Settlement Agreement*, we agreed to grant to Lupin a future license to make and sell our generic versions of SOLODYN® in 45mg, 90mg and 135mg strengths under the SOLODYN® intellectual property rights belonging to us, with the license grant effective November 26, 2011, or earlier under certain conditions. We also agreed to grant to Lupin future licenses to make and sell our generic versions of SOLODYN® in 65mg and 115mg strengths effective in February 2018, or earlier under certain conditions, and our generic versions of SOLODYN® in 55mg (against which Lupin's Paragraph IV Patent Certification was the first received by us), 80mg and 105mg strengths effective in

Table of Contents

February 2019, or earlier under certain conditions. The Settlement Agreement provides that Lupin will be required to pay us royalties based on sales of Lupin's generic SOLODYN® products pursuant to the foregoing licenses.

Pursuant to the Settlement Agreement, the companies agreed to terminate all legal disputes between them relating to SOLODYN®. In addition, Lupin confirmed that our patents relating to SOLODYN® are valid and enforceable, and cover Lupin's activities relating to Lupin's generic SOLODYN® products under an ANDA. Lupin also agreed to be permanently enjoined from any distribution of generic SOLODYN® products in the U.S. except as described above.

On July 21, 2011, we entered into a Joint Development Agreement (the "Joint Development Agreement") with Lupin Limited, on behalf of itself and its affiliates (hereinafter collectively referred to in this paragraph as "Lupin"), whereby we and Lupin will collaborate to develop multiple novel proprietary therapeutic products. Pursuant to the Joint Development Agreement, subject to the terms and conditions contained therein, we will make an up-front \$20 million payment to Lupin and will make additional payments to Lupin of up to \$38 million upon the achievement of certain research, development, regulatory and other milestones, as well as royalty payments on sales of the products covered under the agreement. In addition, we will receive an exclusive, worldwide (excluding India) license on the sale of the products covered under the Joint Development Agreement. The \$20 million up-front payment will be recognized as research and development expense during the three months ended September 30, 2011.

Stock Repurchase Plan

On August 8, 2011, we announced that our Board of Directors approved a Stock Repurchase Plan to purchase up to \$200 million in aggregate value of shares of Medicis Class A common stock. Any repurchases will be made in compliance with the Securities and Exchange Commission's Rule 10b-18.

The number of shares to be repurchased and the timing of repurchases (if any) will depend on a variety of factors, including, but not limited to, stock price, economic and market conditions and corporate and regulatory requirements. The plan does not obligate us to repurchase any common stock. The plan is scheduled to terminate on the earlier of the first anniversary of the plan or the time at which the purchase limit is reached, but may be suspended or terminated at any time at our discretion without prior notice.

Table of Contents

Results of Operations

The following table sets forth certain data as a percentage of net revenues for the periods indicated.

| | Three Months Ended | | Six Months Ended | |
|--|--------------------|--------|------------------|--------|
| | June | June | June | June |
| | 30, | 30, | 30, | 30, |
| | 2011 | 2010 | 2011 | 2010 |
| | (a) | (b) | (c) | (d) |
| Net revenues | 100.0% | 100.0% | 100.0% | 100.0% |
| Gross profit (e) | 90.4 | 90.6 | 90.8 | 90.7 |
| Operating expenses | 59.1 | 52.7 | 61.5 | 52.2 |
| Operating income | 31.3 | 37.9 | 29.3 | 38.5 |
| Other expense, net | | | | 0.1 |
| Interest and investment income (expense), net | 0.1 | (0.2) | 0.1 | (0.1) |
| Income from continuing operations before income tax expense | 31.4 | 37.7 | 29.4 | 38.5 |
| Income tax expense | (13.4) | (14.2) | (12.2) | (14.5) |
| Net income from continuing operations | 18.0 | 23.5 | 17.2 | 24.0 |
| Loss from discontinued operations, net of income tax benefit | (3.0) | (2.6) | (3.7) | (2.7) |
| Net income | 15.0% | 20.9% | 13.5% | 21.3% |

- (a) Included in operating expenses is \$5.5 million (2.9% of net revenues) paid related to a product development agreement with a privately-held U.S. biotechnology company, \$2.0 million (1.0% of net revenues) paid to a Medicis partner related to a product development agreement and \$9.3 million (4.9% of net revenues) of compensation expense related to stock options, restricted stock and stock appreciation rights.
- (b) Included in operating expenses is \$2.1 million (1.2% of net revenues) of compensation expense related to stock options, restricted stock and stock appreciation rights.
- (c) Included in operating expenses is \$7.0 million (2.0% of net revenues) paid to Anacor related to a product development agreement, \$5.5 million (1.5% of net revenues) paid related to a product development agreement with a privately-held U.S. biotechnology company, \$2.0 million (0.6% of net revenues) paid to a Medicis partner related to a product development agreement and \$16.0 million (4.5% of net revenues) of compensation expense related to stock options, restricted stock and stock appreciation rights.
- (d) Included in operating expenses is \$5.1 million (1.5% of net revenues) of compensation expense related to stock options, restricted stock and stock appreciation rights.
- (e) Gross profit does not include amortization of the related intangibles as such expense is included in operating expenses.

Table of Contents*Three Months Ended June 30, 2011 Compared to the Three Months Ended June 30, 2010**Net Revenues*

The following table sets forth our net revenues for the three months ended June 30, 2011 (the second quarter of 2011) and June 30, 2010 (the second quarter of 2010), along with the percentage of net revenues and percentage point change for each of our product categories (dollar amounts in millions):

| | Second Quarter 2011 | Second Quarter 2010 | \$ Change | % Change |
|-----------------------|---------------------------|---------------------------|--------------|-------------|
| Net product revenues | \$ 189.8 | \$ 171.7 | \$ 18.1 | 10.5% |
| Net contract revenues | 1.0 | 1.9 | (0.9) | (47.4)% |
| Total net revenues | \$ 190.8 | \$ 173.6 | \$ 17.2 | 9.9% |

| | Second Quarter 2011 | Second Quarter 2010 | \$ Change | % Change |
|---|---------------------------|---------------------------|--------------|-------------|
| Acne and acne-related dermatological products | \$ 123.1 | \$ 124.8 | \$ (1.7) | (1.4)% |
| Non-acne dermatological products | 57.7 | 41.0 | 16.7 | 40.7% |
| Non-dermatological products (including contract revenues) | 10.0 | 7.8 | 2.2 | 28.2% |
| Total net revenues | \$ 190.8 | \$ 173.6 | \$ 17.2 | 9.9% |

| | Second Quarter 2011 | Second Quarter 2010 | Change |
|---|---------------------------|---------------------------|--------|
| Acne and acne-related dermatological products | 64.5% | 71.9% | (7.4)% |
| Non-acne dermatological products | 30.3% | 23.6% | 6.7% |
| Non-dermatological products (including contract revenues) | 5.2% | 4.5% | 0.7% |
| Total net revenues | 100.0% | 100.0% | |

Net revenues associated with our acne and acne-related dermatological products decreased by \$1.7 million, or 1.4%, during the second quarter of 2011 as compared to the second quarter of 2010, primarily due to a decrease in sales of TRIAZ[®], partially offset by increases in sales of SOLODYN[®] and ZIANA[®]. The decrease in net revenues of TRIAZ[®] was primarily due to our early 2011 discontinuation of TRIAZ[®] as a result of the FDA's requirement that, effective March 4, 2011, prescription benzoyl peroxide products that are not approved through a New Drug Application, such as TRIAZ[®], not be sold as prescription products. The increase in net revenues of SOLODYN[®] was primarily the result of an increase in gross sales of SOLODYN[®] due to increased demand and the FDA approval of

new 55mg, 80mg and 105mg strengths of SOLODYN® on August 27, 2010. The increase in net revenues of ZIANA® was primarily the result of an increase in gross sales of ZIANA®. We also reversed reserves during the second quarter of 2011 of \$3.9 million that were originally recorded during the first quarter of 2011 related to a targeted recall of the product as a result of a notice we received during April 2011 from our contract manufacturer regarding one lot of ZIANA® that went out of specification, as the actual amount of product subject to recall was less than previously estimated. However, this reserve reversal was offset by increased returns and related reserve adjustments on the legacy products within this category.

Table of Contents

Net revenues associated with our non-acne dermatological products increased by \$16.7 million, or 40.7%, during the second quarter of 2011 as compared to the second quarter of 2010 primarily due to increased sales of DYSPO[®] and VANOS[®].

Net revenues associated with our non-dermatological products increased by \$2.2 million, or 28.2%, during the second quarter of 2011 as compared to the second quarter of 2010 primarily due to an increase in sales of BUPHENYL[®], partially offset by a decrease in contract revenues.

Gross Profit

Gross profit represents our net revenues less our cost of product revenue. Our cost of product revenue includes our acquisition cost for the products we purchase from our third party manufacturers and royalty payments made to third parties. Amortization of intangible assets related to products sold is not included in gross profit. Amortization expense related to these intangibles for the second quarter of 2011 and 2010 was approximately \$5.3 million and \$5.2 million, respectively. Product mix plays a significant role in our quarterly and annual gross profit as a percentage of net revenues. Different products generate different gross profit margins, and the relative sales mix of higher gross profit products and lower gross profit products can affect our total gross profit.

The following table sets forth our gross profit for the second quarter of 2011 and 2010, along with the percentage of net revenues represented by such gross profit (dollar amounts in millions):

| | Second Quarter | Second Quarter | \$ | % |
|-------------------|-------------------|-------------------|---------|--------|
| | 2011 | 2010 | Change | Change |
| Gross profit | \$ 172.6 | \$ 157.3 | \$ 15.3 | 9.7% |
| % of net revenues | 90.4% | 90.6% | | |

The increase in gross profit during the second quarter of 2011 as compared to the second quarter of 2010 is primarily due to the \$17.2 million increase in net revenues.

Selling, General and Administrative Expenses

The following table sets forth our selling, general and administrative expenses for the second quarter of 2011 and 2010, along with the percentage of net revenues represented by selling, general and administrative expenses (dollar amounts in millions):

| | Second Quarter | Second Quarter | \$ | % |
|--|-------------------|-------------------|---------|--------|
| | 2011 | 2010 | Change | Change |
| Selling, general and administrative | \$ 90.4 | \$ 77.1 | \$ 13.3 | 17.3% |
| % of net revenues | 47.4% | 44.4% | | |
| Share-based compensation expense included in selling, general and administrative | \$ 8.7 | \$ 2.1 | \$ 6.6 | 314.3% |

Selling, general and administrative expenses increased \$13.3 million, or 17.3%, during the second quarter of 2011 as compared to the second quarter of 2010, and increased as a percentage of net revenues from 44.4% during the second quarter of 2010 to 47.4% during the second quarter of 2011. Included in this increase was a \$10.3 million increase in personnel expenses, including a \$6.6 million increase in stock compensation expense, primarily related to the revaluation of stock appreciation rights (SARs) awards based on changes in the market price of our common stock, a \$3.6 million increase in promotion costs and a decrease of \$0.6 million of other selling, general and administrative costs.

Table of Contents*Research and Development Expenses*

The following table sets forth our research and development expenses for the second quarter of 2011 and 2010 (dollar amounts in millions):

| | Second Quarter 2011 | Second Quarter 2010 | \$ Change | % Change |
|---|-------------------------------|-------------------------------|--------------|-------------|
| Research and development | \$ 15.2 | \$ 7.4 | \$ 7.8 | 105.4% |
| Charges included in research and development | \$ 7.5 | \$ | \$ 7.5 | 100.0% |
| Share-based compensation expense included in research and development | \$ 0.6 | \$ 0.1 | \$ 0.5 | 500.0% |

Included in research and development expenses for the second quarter of 2011 was a \$5.5 million payment related to a product development agreement with a privately-held U.S. biotechnology company and \$2.0 million paid to a Medicis partner related to a product development agreement. We expect research and development expenses to continue to fluctuate from quarter to quarter based on the timing of the achievement of development milestones under license and development agreements, as well as the timing of other development projects and the funds available to support these projects.

Depreciation and Amortization Expenses

Depreciation and amortization expenses during the second quarter of 2011 were \$7.1 million, as compared to \$6.9 million during the second quarter of 2010, primarily due to increased depreciation expense for property and equipment.

Interest and Investment Income

Interest and investment income during the second quarter of 2011 increased \$0.4 million, or 58.8%, to \$1.2 million from \$0.8 million during the second quarter of 2010, due to an increase in the amount of funds available for investment during the second quarter of 2011.

Interest Expense

Interest expense during each of the second quarter of 2011 and the second quarter of 2010 was \$1.1 million. Our interest expense during the second quarter of 2011 and 2010 consisted of interest expense on our Old Notes, which accrue interest at 2.5% per annum, and our New Notes, which accrue interest at 1.5% per annum. In addition, during the second quarter of 2011, approximately \$0.1 million of contingent interest was accrued related to our Old Notes. See Note 12 in our accompanying condensed consolidated financial statements for further discussion on the Old Notes and New Notes.

Income Tax Expense

Our effective tax rate for continuing operations for the second quarter of 2011 was 42.5%, as compared to 37.6% for the second quarter of 2010. The effective tax rate for the second quarter of 2011 reflects the impact of the non-deductibility of a \$5.5 million milestone payment associated with a product development agreement with a privately-held U.S. biotechnology company.

Loss from Discontinued Operations, Net of Income Tax Benefit

Loss from discontinued operations, net of income tax benefit, was \$5.7 million during the second quarter of 2011, as compared to \$4.4 million during the second quarter of 2010. See Note 2 in our accompanying condensed consolidated financial statements for further discussion.

Table of Contents*Six Months Ended June 30, 2011 Compared to the Six Months Ended June 30, 2010**Net Revenues*

The following table sets forth our net revenues for the six months ended June 30, 2011 (the 2011 six months) and June 30, 2010 (the 2010 six months), along with the percentage of net revenues and percentage point change for each of our product categories (dollar amounts in millions):

| | 2011 Six Months | 2010 Six Months | \$ Change | % Change |
|-----------------------|-----------------------|--------------------|--------------|-------------|
| Net product revenues | \$ 353.7 | \$ 335.3 | \$ 18.4 | 5.5% |
| Net contract revenues | 2.0 | 3.8 | (1.8) | (47.4)% |
| Total net revenues | \$ 355.7 | \$ 339.1 | \$ 16.6 | 4.9% |

| | 2011 Six Months | 2010 Six Months | \$ Change | % Change |
|---|-----------------------|--------------------|--------------|-------------|
| Acne and acne-related dermatological products | \$ 226.6 | \$ 245.0 | \$ (18.4) | (7.5)% |
| Non-acne dermatological products | 109.9 | 75.2 | 34.7 | 46.1% |
| Non-dermatological products (including contract revenues) | 19.2 | 18.9 | 0.3 | 1.6% |
| Total net revenues | \$ 355.7 | \$ 339.1 | \$ 16.6 | 4.9% |

| | 2011 Six Months | 2010 Six Months | Change |
|---|-----------------------|--------------------|--------|
| Acne and acne-related dermatological products | 63.7% | 72.2% | (8.5)% |
| Non-acne dermatological products | 30.9% | 22.2% | 8.7% |
| Non-dermatological products (including contract revenues) | 5.4% | 5.6% | (0.2)% |
| Total net revenues | 100.0% | 100.0% | % |

Net revenues associated with our acne and acne-related dermatological products decreased by \$18.4 million, or 7.5%, during the 2011 six months as compared to the 2010 six months primarily as a result of a decrease in net revenues of TRIAZ[®]. The decrease in net revenues of TRIAZ[®] was primarily due to our early 2011 discontinuation of TRIAZ[®] as a result of the FDA's requirement that, effective March 4, 2011, prescription benzoyl peroxide products that are not approved through a New Drug Application, such as TRIAZ[®], not be sold as prescription products.

Net revenues associated with our non-acne dermatological products increased by \$34.7 million, or 46.1%, during the 2011 six months as compared to the 2010 six months, primarily due to increased sales of DYSPORT[®] and VANOS[®].

Gross Profit

Gross profit represents our net revenues less our cost of product revenue. Our cost of product revenue includes our acquisition cost for the products we purchase from our third party manufacturers and royalty payments made to third parties. Amortization of intangible assets related to products sold is not included in gross profit. Amortization

Table of Contents

expense related to these intangibles for the 2011 six months and 2010 six months was approximately \$10.7 million and \$10.4 million, respectively. Product mix plays a significant role in our quarterly and annual gross profit as a percentage of net revenues. Different products generate different gross profit margins, and the relative sales mix of higher gross profit products and lower gross profit products can affect our total gross profit.

The following table sets forth our gross profit for the 2011 six months and 2010 six months, along with the percentage of net revenues represented by such gross profit (dollar amounts in millions):

| | 2011 Six Months | 2010 Six Months | \$ Change | % Change |
|-------------------|--------------------|--------------------|--------------|-------------|
| Gross profit | \$ 323.2 | \$ 307.7 | \$ 15.5 | 5.0% |
| % of net revenues | 90.8% | 90.7% | | |

The increase in gross profit during the 2011 six months as compared to the 2010 six months is primarily due to the \$16.6 million increase in net revenues.

Selling, General and Administrative Expenses

The following table sets forth our selling, general and administrative expenses for the 2011 six months and 2010 six months, along with the percentage of net revenues represented by selling, general and administrative expenses (dollar amounts in millions):

| | 2011 Six Months | 2010 Six Months | \$ Change | % Change |
|--|--------------------|--------------------|--------------|-------------|
| Selling, general and administrative | \$ 175.0 | \$ 149.4 | \$ 25.6 | 17.1% |
| % of net revenues | 49.2% | 44.0% | | |
| Share-based compensation expense included in selling, general and administrative expense | \$ 15.0 | \$ 5.0 | \$ 10.0 | 200.0% |

Selling, general and administrative expenses increased \$25.6 million, or 17.1%, during the 2011 six months as compared to the 2010 six months, and increased as a percentage of net revenues from 44.0% during the 2010 six months to 49.2% during the 2011 six months. Included in this increase was an \$18.8 million increase in personnel expenses, including a \$10.0 million increase in stock compensation expense, primarily related to the revaluation of SARs awards based on changes in the market price of our common stock, a \$2.6 million increase in promotion costs and an increase of \$4.2 million of other selling, general and administrative costs.

Research and Development Expenses

The following table sets forth our research and development expenses for the 2011 six months and 2010 six months (dollar amounts in millions):

| | 2011 Six Months | 2010 Six Months | \$ Change | % Change |
|---|-----------------------|-----------------------|--------------|-------------|
| Research and development | \$ 29.5 | \$ 14.0 | \$ 15.5 | 110.7% |
| Charges included in research and development | \$ 14.5 | \$ | \$ 14.5 | 100.0% |
| Share-based compensation expense included in research and development | \$ 1.0 | \$ 0.1 | \$ 0.9 | 900.0% |

Included in research and development expenses for the 2011 six months was a \$7.0 million payment to Anacor related to a product development agreement, a \$5.5 million payment related to a product development agreement with

a privately-held U.S. biotechnology company and \$2.0 million paid to a Medicis partner related to a

Table of Contents

product development agreement. We expect research and development expenses to continue to fluctuate from quarter to quarter based on the timing of the achievement of development milestones under license and development agreements, as well as the timing of other development projects and the funds available to support these projects.

Depreciation and Amortization Expenses

Depreciation and amortization expenses during the 2011 six months were \$14.4 million, as compared to \$13.6 million during the 2010 six months, primarily due to increased depreciation expense for property and equipment.

Interest and Investment Income

Interest and investment income during the 2011 six months increased \$0.6 million, or 29.5%, to \$2.5 million from \$1.9 million during the 2010 six months, due to an increase in the amount of funds available for investment during the first half of 2011.

Interest Expense

Interest expense during the 2011 six months and the 2010 six months was \$2.2 million and \$2.1 million, respectively. Our interest expense during the 2011 six months and 2010 six months consisted of interest expense on our Old Notes, which accrue interest at 2.5% per annum, and our New Notes, which accrue interest at 1.5% per annum. In addition, during the 2011 six months, approximately \$0.1 million of contingent interest was accrued related to our Old Notes. See Note 12 in our accompanying condensed consolidated financial statements for further discussion on the Old Notes and New Notes.

Other Expense, net

Other expense of \$0.3 million recognized during the 2010 six months represented an other-than-temporary impairment on an asset-backed security investment.

Income Tax Expense

Our effective tax rate for the 2011 six months was 41.5%, as compared to 37.9% for the 2010 six months. The effective tax rate for the 2011 six months reflects the impact of the non-deductibility of a \$5.5 million milestone payment associated with a product development agreement with a privately-held U.S. biotechnology company.

Loss from Discontinued Operations, Net of Income Tax Benefit

Loss from discontinued operations, net of income tax benefit, was \$13.1 million during the 2011 six months, as compared to \$9.1 million during the 2010 six months. See Note 2 in our accompanying condensed consolidated financial statements for further discussion.

Table of Contents

Liquidity and Capital Resources

Overview

The following table highlights selected cash flow components for the second quarter of 2011 and 2010, and selected balance sheet components as of June 30, 2011 and December 31, 2010 (dollar amounts in millions):

| | 2011 Six Months | 2010 Six Months | \$ Change | % Change |
|--|-----------------------|-----------------------|--------------|-------------|
| Cash provided by (used in): | | | | |
| Operating activities | \$ 72.6 | \$ 60.0 | \$ 12.6 | 21.0% |
| Investing activities | (189.2) | (166.4) | (22.8) | (13.7)% |
| Financing activities | 48.4 | (3.5) | 51.9 | 1,482.9% |
| | June 30, 2011 | Dec. 31, 2010 | \$ Change | % Change |
| Cash, cash equivalents, and short-term investments | \$ 805.8 | \$ 703.6 | \$ 102.2 | 14.5% |
| Working capital | 507.2 | 628.4 | (121.2) | (19.3)% |
| Long-term investments | 22.4 | 21.5 | 0.9 | 4.2% |
| 2.5% contingent convertible senior notes due 2032 | 169.1 | 169.1 | | % |
| 1.5% contingent convertible senior notes due 2033 | 0.2 | 0.2 | | % |
| | 40 | | | |

Table of Contents*Working Capital*

Working capital as of June 30, 2011 and December 31, 2010 consisted of the following (dollar amounts in millions):

| | June 30, 2011 | Dec. 31, 2010 | \$ Change | % Change |
|--|------------------|------------------|-------------------|----------------|
| Cash, cash equivalents, and short-term investments | \$ 805.8 | \$ 703.6 | \$ 102.2 | 14.5% |
| Accounts receivable, net | 166.4 | 130.6 | 35.8 | 27.4% |
| Inventories, net | 30.8 | 35.3 | (4.5) | (12.7)% |
| Deferred tax assets, net | 24.6 | 70.5 | (45.9) | (65.1)% |
| Other current assets | 19.3 | 15.2 | 4.1 | 27.0% |
| Assets held for sale from discontinued operations | 10.2 | 13.1 | (2.9) | (22.1)% |
| Total current assets | 1,057.1 | 968.3 | 88.8 | 9.2% |
| Accounts payable | 45.4 | 41.0 | 4.4 | 10.7% |
| Current portion of contingent convertible senior notes | 169.1 | | 169.1 | 100.0% |
| Reserve for sales returns | 78.2 | 60.7 | 17.5 | 28.8% |
| Accrued consumer rebate and loyalty programs | 124.9 | 101.7 | 23.2 | 22.8% |
| Managed care and Medicaid reserves | 51.3 | 49.4 | 1.9 | 3.8% |
| Income taxes payable | | 4.6 | (4.6) | (100.0)% |
| Other current liabilities | 73.8 | 75.2 | (1.4) | (1.9)% |
| Liabilities held for sale from discontinued operations | 7.2 | 7.3 | (0.1) | (1.4)% |
| Total current liabilities | 549.9 | 339.9 | 210.0 | 61.8% |
| Working capital | \$ 507.2 | \$ 628.4 | \$ (121.2) | (19.3)% |

We had cash, cash equivalents and short-term investments of \$805.8 million and working capital of \$507.2 million at June 30, 2011, as compared to \$703.6 million and \$628.4 million, respectively, at December 31, 2010. The increase in cash, cash equivalents and short-term investments was primarily due to the generation of \$72.6 million of operating cash flow and \$54.0 million of proceeds received from stock option exercises during the 2011 six months.

Accounts receivable, net, increased \$35.8 million, or 27.4%, from \$130.6 million at December 31, 2010 to \$166.4 million at June 30, 2011. The increase was primarily due to a \$44.8 million increase in gross sales during the month of June 2011 as compared to the month of December 2010. As our standard payment terms are 30 days, orders that occur during the last month of a quarter are typically not due for payment until after the end of the quarter. Gross sales during the month of June 2011 were \$185.2 million, or 52.4% of the total gross sales for the second quarter of 2011, as compared to gross sales during the month of December 2010 of \$140.4 million, or 45.1% of total gross sales for the fourth quarter of 2010. Days sales outstanding, calculated as accounts receivable, net, as of the end of the reporting period, divided by total gross sales for the quarter, multiplied by the number of days in the quarter, was 43 days as of June 30, 2011 as compared to 39 days as of December 31, 2010. The increase in days sales outstanding was primarily due to the timing of orders placed by customers during the second quarter of 2011 as compared to the fourth quarter of 2010. Although more of the customers purchases during the second quarter of 2011 occurred during the last month of the quarter as compared to the last month of the fourth quarter of 2010, their total purchases for the

second quarter of 2011 were consistent with previous quarters. We sell our products primarily to major wholesalers and retail chain drugstores. We have distribution services agreements with our two largest wholesale customers. We review the supply levels of our significant products sold to major wholesalers by reviewing periodic inventory reports that are supplied to us by our major wholesalers in accordance

Table of Contents

with the distribution services agreements. We rely wholly upon our wholesale and retail chain drugstore customers to effect the distribution allocation of substantially all of our prescription products. We also defer the recognition of revenue for certain sales of inventory into the distribution channel that are in excess of eight (8) weeks of projected demand, and we defer the recognition of revenue of our aesthetics products DYSPO[®], PERLANE[®] and RESTYLANE[®], until our exclusive U.S. distributor, McKesson, ships these products to physicians. There has not been a significant change in inventories in the distribution channel during the quarter ended June 30, 2011.

Management believes existing cash and short-term investments, together with funds generated from operations, should be sufficient to meet operating requirements for the foreseeable future. Our cash and short-term investments are available for dividends, milestone payments related to our product development collaborations, strategic investments, acquisitions of companies or products complementary to our business, the repayment of outstanding indebtedness, repurchases of our outstanding securities and other potential large-scale needs. In addition, we may consider incurring additional indebtedness and issuing additional debt or equity securities in the future to fund potential acquisitions or investments, to refinance existing debt or for general corporate purposes. If a material acquisition or investment is completed, our operating results and financial condition could change materially in future periods. However, no assurance can be given that additional funds will be available on satisfactory terms, or at all, to fund such activities.

As of June 30, 2011, our short-term investments included \$19.9 million of auction rate floating securities. Our auction rate floating securities are debt instruments with a long-term maturity and with an interest rate that is reset in short intervals through auctions. During the three months ended March 31, 2008, we were informed that there was insufficient demand at auction for the auction rate floating securities, and since that time we have been unable to liquidate our holdings in such securities. As a result, these affected auction rate floating securities are now considered illiquid, and we could be required to hold them until they are redeemed by the holder at maturity or until a future auction on these investments is successful. During the 2011 six months, we liquidated \$2.0 million of our auction rate floating securities at par.

Operating Activities

Net cash provided by operating activities during the 2011 six months was approximately \$72.6 million, compared to cash provided by operating activities of approximately \$60.0 million during the 2010 six months. The following is a summary of the primary components of cash provided by operating activities during the 2011 six months and 2010 six months (in millions):

| | 2011 Six Months | 2010 Six Months |
|--|-----------------------|--------------------|
| Income taxes paid | \$ (38.0) | \$ (47.7) |
| Payment made to Anacor related to development agreement | (7.0) | |
| Payment made related to development agreement with a privately-held U.S. biotechnology company | (5.5) | |
| Payment made to a Medicis partner related to a development agreement | (2.0) | |
| Increase in accounts receivable | (36.9) | (42.8) |
| Increase in reserve for returns | 17.5 | 1.1 |
| Increase in accrued consumer rebates and loyalty programs | 23.2 | 17.1 |
| Decrease in other current liabilities | (17.3) | (2.3) |
| Cash used in operating activities from discontinued operations | (10.0) | (5.3) |
| Other cash provided by operating activities | 148.6 | 139.9 |
| Cash provided by operating activities | \$ 72.6 | \$ 60.0 |

Investing Activities

Net cash used in investing activities during the 2011 six months was approximately \$189.2 million, compared to net cash used in investing activities during the 2010 six months of \$166.4 million. The change was primarily due to the net purchases and sales of our short-term and long-term investments during the respective periods.

Table of Contents*Financing Activities*

Net cash provided by financing activities during the 2011 six months was \$48.4 million, compared to net cash used in financing activities of \$3.5 million during the 2010 six months. Proceeds from the exercise of stock options were \$54.0 million during the 2011 six months compared to \$2.2 million during the 2010 six months. Dividends paid during the 2011 six months were \$8.5 million and dividends paid during the 2010 six months were \$6.0 million.

Contingent Convertible Senior Notes and Other Long-Term Commitments

We have two outstanding series of Contingent Convertible Senior Notes, consisting of \$169.1 million principal amount of 2.5% Contingent Convertible Senior Notes due 2032 (the Old Notes) and \$0.2 million principal amount of 1.5% Contingent Convertible Senior Notes due 2033 (the New Notes). The New Notes and the Old Notes are unsecured and do not contain any restrictions on the incurrence of additional indebtedness or the repurchase of our securities, and do not contain any financial covenants. The Old Notes do not contain any restrictions on the payment of dividends. The New Notes require an adjustment to the conversion price if the cumulative aggregate of all current and prior dividend increases above \$0.025 per share would result in at least a one percent (1%) increase in the conversion price. This threshold has not been reached and no adjustment to the conversion price has been made.

On June 4, 2012 and 2017, or upon the occurrence of a change in control, holders of the Old Notes may require us to offer to repurchase their Old Notes for cash. On June 4, 2013 and 2018, or upon the occurrence of a change in control, holders of the New Notes may require us to offer to repurchase their New Notes for cash. Under GAAP, if an obligation is due on demand or will be due on demand within one year from the balance sheet date, even though liquidation may not be expected within that period, it should be classified as a current liability. Accordingly, the outstanding balance of Old Notes along with the deferred tax liability associated with accelerated interest deductions on the Old Notes will be classified as a current liability during the respective twelve month periods prior to June 4, 2012 and June 4, 2017. As of June 30, 2011, \$169.1 million of the Old Notes and \$57.9 million of deferred tax liabilities were classified as current liabilities in our condensed consolidated balance sheets. The \$57.9 million of deferred tax liabilities were included within current deferred tax assets, net. If all of the Old Notes are put back to us on June 4, 2012, we would be required to pay \$169.1 million in outstanding principal, plus accrued interest. We would also be required to pay the accumulated deferred tax liability related to the Old Notes.

During the quarter ended June 30, 2011, the Old Notes met the criteria for the right of conversion into shares of the Company's Class A common stock. This right of conversion of the holders of the Old Notes was triggered by the stock closing above \$31.96 on 20 of the last 30 trading days and the last trading day of the quarter ended June 30, 2011. The holders of Old Notes have this conversion right only until September 30, 2011. At the end of each future quarter, the conversion rights will be reassessed in accordance with the bond indenture agreement to determine if the conversion trigger rights have been achieved. During the quarter ended June 30, 2011, the New Notes did not meet the criteria for the right of conversion.

Except for the New Notes, we had only \$39.0 million of long-term liabilities at June 30, 2011, and, except for the Old Notes, we had \$380.7 million of current liabilities at June 30, 2011. Our other commitments and planned expenditures consist principally of payments we will make in connection with strategic collaborations and research and development expenditures, and we will continue to invest in sales and marketing infrastructure.

Dividends

We do not have a dividend policy. Prior to July 2003, we had not paid a cash dividend on our common stock. Since July 2003, we have paid quarterly cash dividends aggregating approximately \$68.4 million on our common stock. In addition, on June 8, 2011, we announced that our Board of Directors had declared a cash dividend of \$0.08 per issued and outstanding share of common stock, which was paid on July 29, 2011, to our stockholders of record at the close of business on July 1, 2011. Any future determinations to pay cash dividends will be at the discretion of our Board of Directors and will be dependent upon our financial condition, operating results, capital requirements and other factors that our Board of Directors deems relevant.

Table of Contents

Fair Value Measurements

We utilize unobservable (Level 3) inputs in determining the fair value of our auction rate floating security investments, which totaled \$19.9 million at June 30, 2011. These securities were included in long-term investments at June 30, 2011.

Our auction rate floating securities are classified as available-for-sale securities and are reflected at fair value. In prior periods, due to the auction process which took place every 30-35 days for most securities, quoted market prices were readily available, which would qualify as Level 1 under ASC 820, *Fair Value Measurements and Disclosure*. However, due to events in credit markets that began during the first quarter of 2008, the auction events for most of these instruments failed, and, therefore, we determined the estimated fair values of these securities, beginning in the first quarter of 2008, utilizing a discounted cash flow analysis. These analyses consider, among other items, the collateralization underlying the security investments, the expected future cash flows, including the final maturity, associated with the securities, and the expectation of the next time the security is expected to have a successful auction. These securities were also compared, when possible, to other observable market data with similar characteristics to the securities held by us. Due to these events, we reclassified these instruments as Level 3 during the first quarter of 2008.

Off-Balance Sheet Arrangements

As of June 30, 2011, we are not involved in any off-balance sheet arrangements, as defined in Item 303(a)(4)(ii) of Securities and Exchange Commission (SEC) Regulation S-K.

Critical Accounting Policies and Estimates

The discussion and analysis of our financial condition and results of operations are based upon our condensed consolidated financial statements, which have been prepared in conformity with U.S. generally accepted accounting principles. The preparation of the condensed consolidated financial statements requires us to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. On an ongoing basis, we evaluate our estimates related to sales allowances, chargebacks, rebates, returns and other pricing adjustments, depreciation and amortization and other contingencies and litigation. We base our estimates on historical experience and various other factors related to each circumstance. Actual results could differ from those estimates based upon future events, which could include, among other risks, changes in the regulations governing the manner in which we sell our products, changes in the health care environment and managed care consumption patterns. Our significant accounting policies are described in Note 2 to the consolidated financial statements included in our Form 10-K for the year ended December 31, 2010. There were no new significant accounting estimates in the second quarter of 2011, nor were there any material changes to the critical accounting policies and estimates discussed in our Form 10-K for the year ended December 31, 2010.

Items Deducted From Gross Revenue

Our accounting policies for revenue recognition have a significant impact on our reported results and rely on certain estimates that require complex and subjective judgment on the part of our management. If the levels of product returns, inventory in the distribution channel, cash discounts, chargebacks, managed care and Medicaid rebates and consumer rebate and loyalty programs fluctuate significantly and/or if our estimates do not adequately reserve for these reductions of gross product revenues, our reported net product revenues could be negatively affected.

Table of Contents

The following table shows the activity of each reserve, associated with the various sales provisions that serve to reduce our accounts receivable balance or increase our accrued expenses or deferred revenue, for the three months ended June 30, 2011 and 2010 (in thousands):

| | Reserve for Sales Returns | Deferred Revenue | Sales Discounts Reserve | Chargebacks Reserve | Managed Care & Medicaid Rebates Reserve | Consumer Rebate and Loyalty Programs | Total |
|-----------------------------|--|-----------------------------|--|--------------------------------|--|---|--------------|
| Balance at Mar. 31, 2011 | \$ 73,802 | \$ 4,217 | \$ 2,351 | \$ 1,122 | \$ 49,156 | \$ 121,704 | \$ 252,352 |
| Actual | (13,069) | | (5,667) | (1,560) | (22,210) | (108,559) | (151,065) |
| Provision | 17,487 | (1,776) | 6,971 | 1,927 | 24,293 | 111,777 | 160,679 |
| Balance at June 30, 2011 | \$ 78,220 | \$ 2,441 | \$ 3,655 | \$ 1,489 | \$ 51,239 | \$ 124,922 | \$ 261,966 |
| | Reserve for Sales Returns | Deferred Revenue | Sales Discounts Reserve | Chargebacks Reserve | Managed Care & Medicaid Rebates Reserve | Consumer Rebate and Loyalty Programs | Total |
| Balance at Mar. 31, 2010 | \$ 43,716 | \$ 2,561 | \$ 2,365 | \$ 1,148 | \$ 48,964 | \$ 94,582 | \$ 193,336 |
| Actual | (8,455) | | (5,185) | (1,028) | (26,517) | (77,011) | (118,196) |
| Provision | 13,933 | (1,254) | 5,778 | 801 | 21,963 | 72,793 | 114,014 |
| Balance at June 30, 2010 | \$ 49,194 | \$ 1,307 | \$ 2,958 | \$ 921 | \$ 44,410 | \$ 90,364 | \$ 189,154 |

The provision for product returns was \$17.5 million, or 5.0% of gross product sales, and \$13.9 million, or 4.8% of gross product sales, for the three months ended June 30, 2011 and 2010, respectively. The reserve for product returns increased \$4.4 million, from \$73.8 million as of March 31, 2011 to \$78.2 million as of June 30, 2011. The increase in the provision during the comparable periods and in the reserve during the three months ended June 30, 2011 was primarily related to additional estimated required reserves for newly-launched products.

The provision for cash discounts was \$7.0 million, or 2.0% of gross product sales, and \$5.8 million, or 2.0% of gross product sales, for the three months ended June 30, 2011 and 2010, respectively. The reserve for cash discounts increased \$1.3 million, from \$2.4 million as of March 31, 2011 to \$3.7 million as of June 30, 2011. The increase in the provision during the comparable periods was due to an increase in gross product sales. The balance in the reserve for

sales discounts at the end of a quarterly period is related to the amount of accounts receivable that is outstanding at that date that is still eligible for the cash discounts to be taken by the customers. The fluctuation in the reserve for sales discounts between periods is normally reflective of increases or decreases in the related eligible outstanding accounts receivable amounts at the comparable dates.

The provision for consumer rebates and loyalty programs was \$111.8 million, or 31.8% of gross product sales, and \$72.8 million, or 25.0% of gross product sales, for the three months ended June 30, 2011 and 2010,

Table of Contents

respectively. The reserve for consumer rebates and loyalty programs increased \$3.2 million, from \$121.7 million as of March 31, 2011 to \$124.9 million as of June 30, 2011. The increase in the provision during the comparable periods and in the reserve during the three months ended June 30, 2011 was primarily due to the continued growth in consumer rebate programs related to our SOLODYN®, ZIANA® RESTYLANE® and PERLANE® products.

The following table shows the activity of each reserve, associated with the various sales provisions that serve to reduce our accounts receivable balance or increase our accrued expenses or deferred revenue, for the six months ended June 30, 2011 and 2010 (in thousands):

| | Reserve for Sales Returns | Deferred Revenue | Sales Discounts Reserve | Chargebacks Reserve | Managed Care & Medicaid Rebates Reserve | Consumer Rebate and Loyalty Programs | Total |
|-----------------------------|--|-----------------------------|--|--------------------------------|--|---|--------------|
| Balance at Dec. 31, 2010 | \$ 60,692 | \$ 582 | \$ 2,830 | \$ 1,151 | \$ 49,375 | \$ 101,678 | \$ 216,308 |
| Actual | (25,097) | | (12,724) | (2,834) | (47,439) | (189,182) | (277,276) |
| Provision | 42,625 | 1,859 | 13,549 | 3,172 | 49,303 | 212,426 | 322,934 |
| Balance at June 30, 2011 | \$ 78,220 | \$ 2,441 | \$ 3,655 | \$ 1,489 | \$ 51,239 | \$ 124,922 | \$ 261,966 |
| | Reserve for Sales Returns | Deferred Revenue | Sales Discounts Reserve | Chargebacks Reserve | Managed Care & Medicaid Rebates Reserve | Consumer Rebate and Loyalty Programs | Total |
| Balance at Dec. 31, 2009 | \$ 48,062 | \$ 1,263 | \$ 2,160 | \$ 688 | \$ 47,078 | \$ 73,311 | \$ 172,562 |
| Actual | (13,008) | | (10,397) | (2,181) | (47,790) | (129,981) | (203,357) |
| Provision | 14,140 | 44 | 11,195 | 2,414 | 45,122 | 147,034 | 219,949 |
| Balance at June 30, 2010 | \$ 49,194 | \$ 1,307 | \$ 2,958 | \$ 921 | \$ 44,410 | \$ 90,364 | \$ 189,154 |

The provision for product returns was \$42.6 million, or 6.2% of gross product sales, and \$14.1 million, or 2.5% of gross product sales, for the six months ended June 30, 2011 and 2010, respectively. The reserve for product returns increased \$17.5 million, from \$60.7 million as of December 31, 2010 to \$78.2 million as of June 30, 2011. The increase in the provision during the comparable periods and in the reserve during the six months ended June 30, 2011 was primarily related to additional estimated required reserves for newly-launched products.

Edgar Filing: MEDICIS PHARMACEUTICAL CORP - Form 10-Q

The provision for cash discounts was \$13.5 million, or 2.0% of gross product sales, and \$11.2 million, or 2.0% of gross product sales, for the six months ended June 30, 2011 and 2010, respectively. The reserve for cash discounts increased \$0.9 million, from \$2.8 million as of December 31, 2010 to \$3.7 million as of June 30, 2011. The increase in the provision during the comparable periods was due to an increase in gross product sales.

The provision for consumer rebates and loyalty programs was \$212.4 million, or 30.7% of gross product sales, and \$147.0 million, or 25.9% of gross product sales, for the six months ended June 30, 2011 and 2010,

Table of Contents

respectively. The reserve for consumer rebates and loyalty programs increased \$23.2 million, from \$101.7 million as of December 31, 2010 to \$124.9 million as of June 30, 2011. The increase in the provision during the comparable periods and in the reserve during the six months ended June 30, 2011 was primarily due to the continued growth in consumer rebate programs related to our SOLODYN[®], ZIANA[®] RESTYLANE[®] and PERLANE[®] products.

Recent Accounting Pronouncements

In May 2011, the FASB issued Accounting Standards Update (ASU) No. 2011-04, *Amendments to Achieve Common Fair Value Measurement and Disclosure Requirements in U.S. GAAP and International Financial Reporting Standards* (Topic 820) *Fair Value Measurement*, to provide a consistent definition of fair value and ensure that the fair value measurement and disclosure requirements are similar between U.S. GAAP and International Financial Reporting Standards. ASU No. 2011-04 changes certain fair value measurement principles and enhances the disclosure requirements, particularly for level 3 fair value measurements. ASU No. 2011-04 is effective for interim and annual reporting periods beginning after December 15, 2011 and must be applied prospectively. We are currently assessing what impact, if any, the revised guidance will have on our results of operations and financial condition.

In June 2011, the FASB issued ASU No. 2011-05, *Comprehensive Income* (Topic 220): *Presentation of Comprehensive Income*. The updated guidance amends the FASB Accounting Standards Codification (Codification) to allow an entity the option to present the total of comprehensive income, the components of net income, and the components of other comprehensive income either in a single continuous statement of comprehensive income or in two separate but consecutive statements. In both alternatives, an entity is required to present each component of net income along with total net income, each component of other comprehensive income along with a total for other comprehensive income, and a total amount for comprehensive income. ASU No. 2011-05 eliminates the option to present the components of other comprehensive income as part of the statement of changes in stockholders' equity. The amendments to the Codification in the ASU do not change the items that must be reported in other comprehensive income or when an item of other comprehensive income must be reclassified to net income. ASU No. 2011-05 will be applied retrospectively. ASU No. 2011-05 is effective for annual reporting periods beginning after December 15, 2011, with early adoption permitted, and will be applied retrospectively. It is expected that the adoption of this amendment will only impact the presentation of comprehensive income within our consolidated financial statements.

Forward Looking Statements

This Quarterly Report on Form 10-Q and other documents we file with the SEC include forward-looking statements. These include statements relating to future actions, prospective products or product approvals, future performance or results of current and anticipated products, sales and marketing efforts, expenses, the outcome of contingencies, such as legal proceedings, and financial results. From time to time, we also may make forward-looking statements in press releases or written statements, or in our communications and discussions with investors and analysts in the normal course of business through meetings, webcasts, phone calls and conference calls. All statements other than statements of historical fact are, or may be deemed to be, forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the Exchange Act). These statements are based on certain assumptions made by us based on our experience and perception of historical trends, current conditions, expected future developments and other factors we believe are appropriate in the circumstances. We caution you that actual outcomes and results may differ materially from what is expressed, implied or forecast by our forward-looking statements. Such statements are subject to a number of assumptions, risks and uncertainties, many of which are beyond our control. You can identify these statements by the fact that they do not relate strictly to historical or current facts. They use words such as anticipate, estimate, expect, project, intend, plan, believe, will, should, outlook, could, target, and other words and terms of similar connection with any discussion of future operations or financial performance. Among the factors that could cause actual results to differ materially from our forward-looking statements are the following:

- development and launch of new competitive products, including over-the-counter or generic competitor products;

- the ability to compete against generic and other branded products;

Table of Contents

increases or decreases in the expected costs to be incurred in connection with the research and development, clinical trials, regulatory approvals, commercialization and marketing of our products;

the success of research and development activities, including the development of additional forms of SOLODYN[®], and our ability to obtain regulatory approvals;

the speed with which regulatory authorizations and product launches may be achieved;

changes in the FDA's position on the safety or effectiveness of our products;

changes in our product mix;

the anticipated size of the markets and demand for our products;

changes in prescription levels;

the impact of acquisitions, divestitures and other significant corporate transactions, including the disposition of LipoSonix;

the effect of economic changes generally and in hurricane-affected areas;

manufacturing or supply interruptions;

importation of other dermal filler or botulinum toxin products, including the unauthorized distribution of products approved in countries neighboring the U.S.;

changes in the prescribing or procedural practices of dermatologists and/or plastic surgeons, including prescription levels;

the ability to successfully market both new products and existing products;

difficulties or delays in manufacturing and packaging of our products, including delays and quality control lapses of third party manufacturers and suppliers of our products;

the availability of product supply or changes in the cost of raw materials;

trends toward managed care and health care cost containment, including health care initiatives and other third-party cost-containment pressures that could impose financial burdens or cause us to sell our products at lower prices, resulting in decreased revenues;

inadequate protection of our intellectual property or challenges to the validity or enforceability of our proprietary rights and our ability to secure patent protection from filed patent applications for our primary products, including SOLODYN[®];

possible introduction of generic versions of our products, including SOLODYN[®];

possible federal and/or state legislation or regulatory action affecting, among other things, the Company's ability to enter into agreements with companies introducing generic versions of the Company's products as well as pharmaceutical pricing, federal pharmaceutical contracts, mandatory discounts, and reimbursement, including

under Medicaid and Medicare and involuntary approval of prescription medicines for over-the-counter use;

legal defense costs, insurance expenses, settlement costs and the risk of an adverse decision or settlement related to product liability, patent protection, government investigations, and other legal proceedings (see Note 17 in our accompanying condensed consolidated financial statements and Part II, Item 1, Legal Proceedings);

changes in U.S. generally accepted accounting principles;

additional costs related to compliance with changing regulation of corporate governance and public financial disclosure;

any changes in business, political and economic conditions due to the threat of future terrorist activity in the U.S. and other parts of the world;

access to available and feasible financing on a timely basis;

the availability of product acquisition or in-licensing opportunities;

the risks and uncertainties normally incident to the pharmaceutical and medical device industries, including product liability claims;

the risks and uncertainties associated with obtaining necessary FDA approvals;

the inability to obtain required regulatory approvals for any of our pipeline products;

unexpected costs and expenses, or our ability to limit costs and expenses as our business continues to grow;

decreases in revenues associated with the Company's early 2011 discontinuation of TRIAZOLAM and decision to no longer promote PLEXION®;

downturns in general economic conditions that negatively affect our dermal restorative and branded prescription products, and our ability to accurately forecast our financial performance as a result;

changes in our stock price, economic or other market conditions or corporate or regulatory requirements affecting our ability to consummate repurchases under our Stock Repurchase Plan;

failure to comply with our corporate integrity agreement, which could result in substantial civil or criminal penalties and our being excluded from government health care programs, which could materially reduce our sales and adversely affect our financial condition and results of operations; and

the inability to successfully integrate newly-acquired entities.

Table of Contents

We undertake no obligation to publicly update forward-looking statements, whether as a result of new information, future events or otherwise. You are advised, however, to review any future disclosures contained in the reports that we file with the SEC. Our Annual Report on Form 10-K for the year ended December 31, 2010, and this Quarterly Report contain discussions of various risks relating to our business that could cause actual results to differ materially from expected and historical results, which you should review. You should understand that it is not possible to predict or identify all such risks. Consequently, you should not consider any such list or discussion to be a complete set of all potential risks or uncertainties.

Item 3. Quantitative and Qualitative Disclosures About Market Risk

As of June 30, 2011, there were no material changes to the information previously reported under Item 7A in our Annual Report on Form 10-K for the year ended December 31, 2010.

Item 4. Controls and Procedures

We maintain disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) of the Exchange Act) that are designed to ensure that information required to be disclosed in reports filed by us under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC's rules and forms and that such information is accumulated and communicated to management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow for timely decisions regarding required disclosure. Our Chief Executive Officer and Chief Financial Officer, with the participation of other members of management, evaluated the effectiveness of our disclosure controls and procedures as of June 30, 2011, and have concluded that, as of such date, our disclosure controls and procedures were effective to ensure that the information we are required to disclose in reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC's rules and forms.

Although the management of the Company, including the Chief Executive Officer and the Chief Financial Officer, believes that our disclosure controls and internal controls currently provide reasonable assurance that our desired control objectives have been met, management does not expect that our disclosure controls or internal controls will prevent all errors and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within the Company have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the controls. The design of any system of controls is also based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions.

During the three months ended June 30, 2011, there was no change in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) of the Exchange Act) that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

Table of Contents**Part II. Other Information**

Item 1. Legal Proceedings

Lupin SOLODYN® Litigation

On October 8, 2009, we received a Paragraph IV Patent Certification from Lupin Ltd. (Lupin) advising that Lupin had filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) for generic versions of SOLODYN® in 45mg, 90mg, and 135mg strengths. Lupin did not advise us as to the timing or status of the FDA's review of its filing, or whether it has complied with FDA requirements for proving bioequivalence. Lupin's Paragraph IV Patent Certification alleges that our U.S. Patent No. 5,908,838 (the 838 Patent) is invalid. Lupin's Paragraph IV Patent Certification also alleges that our U.S. Patent Nos. 7,541,347, (the "347 Patent) and 7,544,373 (the 373 Patent) are not infringed by Lupin's manufacture, importation, use, sale and/or offer for sale of the products for which its ANDA was submitted. On November 17, 2009, we filed suit against Lupin in the United States District Court for the District of Maryland seeking an adjudication that Lupin has infringed one or more claims of the 838 Patent by submitting to the FDA its ANDA for generic versions of SOLODYN® in 45mg, 90mg and 135mg strengths. The relief we requested includes a request for a permanent injunction preventing Lupin from infringing the 838 Patent by selling generic versions of SOLODYN®. As a result of the filing of the suit, we believe that the ANDA cannot be approved by the FDA until after the expiration of a 30-month stay period or a court decision that the patent is invalid or not infringed.

On November 24, 2009, we received a Paragraph IV Patent Certification from Lupin, advising that Lupin had filed a supplement or amendment to its earlier filed ANDA assigned ANDA number 91-424 with the FDA for a generic version of SOLODYN® in 65mg strength. Lupin has not advised us as to the timing or status of the FDA's review of its filing, or whether Lupin has complied with FDA requirements for proving bioequivalence. Lupin's Paragraph IV Patent Certification alleges that our 838 Patent is invalid. Lupin's submission amends an ANDA already subject to a 30-month stay. As such, we believe that the supplement or amendment cannot be approved by the FDA until after the expiration of the 30-month period or a court decision that the patent is invalid or not infringed.

On December 23, 2009, we received a Paragraph IV Patent Certification from Lupin advising that Lupin had filed a supplement or amendment to its earlier filed ANDA assigned ANDA number 91-424 with the FDA for a generic version of SOLODYN® in 115mg strength. Lupin has not advised us as to the timing or status of the FDA's review of its filing, or whether Lupin has complied with FDA requirements for proving bioequivalence. Lupin's Paragraph IV Patent Certification alleges that the 838 Patent is invalid. Lupin's Paragraph IV Patent Certification also alleges that the 347 Patent and 373 Patent are not infringed by Lupin's manufacture, importation, use, sale and/or offer for sale of the products for which the supplement or amendment was submitted. Lupin's submission amends an ANDA already subject to a 30-month stay. As such, we believe that the supplement or amendment cannot be approved by the FDA until after the expiration of the 30-month period or a court decision that the patent is invalid or not infringed. On December 28, 2009, we amended our complaint against Lupin seeking an adjudication that Lupin has infringed one or more claims of the 838 Patent by submitting its supplement or amendment to its ANDA for a generic version of SOLODYN® in 65mg strength. On February 2, 2010, we amended our complaint against Lupin seeking an adjudication that Lupin has infringed one or more claims of the 838 Patent by submitting its supplement or amendment to its earlier filed ANDA for a generic version of SOLODYN® in 115mg strength.

On July 1, 2010, we amended our complaint against Lupin in the United States District Court for the District of Maryland relating to Lupin's filing of its ANDA, and amendments or supplements thereto, for generic versions of SOLODYN® in 45mg, 65mg, 90mg, 115mg and 135mg strengths. We amended the complaint to assert new claims 19, 21, 23, 25 and 27-34 of the 838 Patent included in an Ex Parte Reexamination Certificate we received from the USPTO on June 1, 2010 in connection with a reexamination of the 838 Patent by the USPTO at the request of a third party. The complaint seeks an adjudication that Lupin has infringed one or more claims of the 838 Patent, including the new claims, by submitting the ANDA, and amendments or supplements thereto, to the FDA.

On September 17, 2010, we received an additional Paragraph IV Patent Certification from Lupin advising that Lupin had filed a supplement or amendment to its earlier filed ANDA assigned ANDA number 91-424 with the FDA for generic versions of SOLODYN® in 45mg, 65mg, 90mg, 115mg and 135mg strengths. Lupin's Paragraph IV Patent Certification alleges that our U.S. Patent No. 7,790,705 (the 705 Patent), which was issued to us by the

Table of Contents

U.S. Patent and Trademark Office (USPTO) on September 7, 2010, will not be infringed by Lupin's manufacture, use, sale and/or importation of the products for which the supplement or amendment was submitted. Lupin's submission amends an ANDA already subject to a 30-month stay. As such, we believe that the supplement or amendment cannot be approved by the FDA until after the expiration of the 30-month period or a court decision that the patent is invalid or not infringed.

On October 18, 2010, we amended our complaint against Lupin in the United States District Court for the District of Maryland relating to Lupin's filing of its ANDA, and amendments or supplements thereto for generic versions of SOLODYN® in 45mg, 65mg, 90mg, 115mg and 135mg strengths. We amended the complaint to allege that Lupin has infringed one or more claims of the 705 Patent by submitting its ANDA, and amendments or supplements thereto, to the FDA to obtain approval for the commercial manufacture, use, offer for sale, sale, or distribution in and/or importation into the United States of its generic versions of SOLODYN® before the expiration of the 705 Patent.

On December 3, 2010, we received a Paragraph IV Patent Certification from Lupin advising that Lupin had filed a supplement or amendment to its earlier filed ANDA assigned ANDA number 91-424 with the FDA for generic versions of SOLODYN® in 55mg and 80mg strengths. Lupin has not advised us as to the timing or status of the FDA's review of its filing, or whether Lupin has complied with FDA requirements for proving bioequivalence. Lupin's Paragraph IV Patent Certification alleges that the 838 Patent is invalid. Lupin's Paragraph IV Patent Certification also alleges that the 705 Patent will not be infringed by Lupin's manufacture, use, sale and/or importation of the products for which the supplement or amendment was submitted. Lupin's submission amends an ANDA already subject to a 30-month stay. As such, we believe that the supplement or amendment cannot be approved by the FDA until after the expiration of the 30-month period or a court decision that the patents are invalid or not infringed. On January 10, 2011, we amended our complaint against Lupin seeking an adjudication that Lupin has infringed one or more claims of the 838 Patent and the 705 Patent by filing the supplement or amendment to its earlier filed ANDA assigned ANDA number 91-424 for generic versions of SOLODYN® in 55mg and 80mg strengths.

On January 24, 2011, we received a Paragraph IV Patent Certification from Lupin advising that Lupin had filed a supplement or amendment to its earlier filed ANDA assigned ANDA number 91-424 with the FDA for a generic version of SOLODYN® in 105mg strength. Lupin has not advised us as to the timing or status of the FDA's review of its filing, or whether Lupin has complied with FDA requirements for proving bioequivalence. Lupin's Paragraph IV Patent Certification alleges that the 838 Patent is invalid. Lupin's Paragraph IV Patent Certification also alleges that the 705 Patent will not be infringed by Lupin's manufacture, use, sale and/or importation of the products for which the supplement or amendment was submitted. Lupin's submission amends an ANDA already subject to a 30-month stay. As such, we believe that the supplement or amendment cannot be approved by the FDA until after the expiration of the 30-month period or a court decision that the patents are invalid or not infringed. On March 2, 2011, we amended our complaint against Lupin seeking an adjudication that Lupin has infringed one or more claims of the 838 Patent and the 705 Patent by filing the supplement or amendment to its earlier filed ANDA assigned ANDA number 91-424 for generic versions of SOLODYN® in 105mg strength.

On February 2, 2011, the Maryland Court issued an Order staying the litigation through and including April 1, 2011, to permit us and Lupin to discuss settlement of the litigation. On March 24, 2011, we and Lupin jointly requested that the Court extend the stay for an additional period through and including May 16, 2011, which was subsequently approved by the Court. On June 20, 2011, the Court issued a further Order staying the litigation through and including July 18, 2011.

On April 19, 2011, we received a Paragraph IV Patent Certification from Lupin advising that Lupin had filed a supplement or amendment to its earlier filed ANDA assigned ANDA number 91-424 with the FDA for generic versions of SOLODYN® in 45mg, 55mg, 65mg, 80mg, 90mg, 105mg, 115mg and 135 mg strengths. Lupin has not advised us as to the timing or status of the FDA's review of its filing, or whether Lupin has complied with FDA requirements for proving bioequivalence. Lupin's Paragraph IV Patent Certification alleges that our newly issued U.S. Patent No. 7,919,483 (the 483 Patent), which was issued to us by the USPTO on April 5, 2011, will not be infringed by Lupin's manufacture, use, sale and/or importation of the products for which the supplement or amendment was submitted. The expiration date for the 483 Patent is in February 2027. We are evaluating the details of Lupin's

certification letter and considering our options. Lupin's submission amends an ANDA already subject to a 30-month stay. As such, we believe that the amendment cannot be approved by the FDA until after the expiration of the 30-month period or a court decision that the patent is invalid or not infringed.

Table of Contents

On July 21, 2011, we entered into a License and Settlement Agreement (the *Lupin Settlement Agreement*) with Lupin and Lupin Pharmaceuticals, Inc. (together referred to as *Lupin* hereunder). Under the terms of the *Lupin Settlement Agreement*, we agreed to grant to Lupin a future license to make and sell its generic versions of SOLODYN® in 45mg, 90mg, and 135mg strengths under the SOLODYN® intellectual property rights belonging to us, with the license grant effective November 26, 2011, or earlier under certain conditions. We also agreed to grant to Lupin future licenses to make and sell its generic versions of SOLODYN® in 65mg and 115mg strengths effective in February 2018, or earlier under certain conditions, and its generic versions of SOLODYN® in 55mg (against which Lupin's Paragraph IV Patent Certification was the first received by us), 80mg and 105mg strengths effective in February 2019, or earlier under certain conditions. The *Lupin Settlement Agreement* provides that Lupin will be required to pay us royalties based on sales of Lupin's generic SOLODYN® products pursuant to the foregoing licenses. Pursuant to the *Lupin Settlement Agreement*, the companies agreed to terminate all legal disputes between them relating to SOLODYN®. In addition, Lupin confirmed that our patents relating to SOLODYN® are valid and enforceable, and cover Lupin's activities relating to Lupin's generic SOLODYN® products under its ANDA. Lupin also agreed to be permanently enjoined from any distribution of generic SOLODYN® products in the U.S. except as described above.

Aurobindo SOLODYN® Litigation

On October 26, 2010, we received a Paragraph IV Patent Certification from Aurobindo Pharma Limited (Aurobindo Pharma) advising that Aurobindo Pharma had filed an ANDA with the FDA for generic versions of SOLODYN® in 45mg, 65mg, 90mg, 115mg and 135mg strengths. Aurobindo Pharma has not advised us as to the timing or status of the FDA's review of its filing, or whether it has complied with FDA requirements for proving bioequivalence. Aurobindo Pharma's Paragraph IV Patent Certification alleges that the 838 Patent is invalid. Aurobindo Pharma's Paragraph IV Patent Certification also alleges that the 347 Patent, 373 Patent and 705 Patent are not infringed by Aurobindo Pharma's manufacture, importation, use, sale and/or offer for sale of the products for which the ANDA was submitted.

On December 3, 2010, we filed suit against Aurobindo Pharma and Aurobindo Pharma USA, Inc. (together, Aurobindo) in the United States District Court for the District of Delaware. On December 6, 2010, we also filed suit against Aurobindo in the United States District Court for the District of New Jersey. The suits seek an adjudication that Aurobindo has infringed one or more claims of the 838 Patent and the 705 Patent by submitting to the FDA an ANDA for generic versions of SOLODYN® in 45mg, 65mg, 90mg, 115mg and 135mg strengths. The relief we requested includes a request for a permanent injunction preventing Aurobindo from infringing the asserted claims of the 838 Patent and the 705 Patent by engaging in the manufacture, use, importation, offer to sell, sale or distribution of generic versions of SOLODYN® before the expiration of the patents.

On June 1, 2011, we received a Paragraph IV Patent Certification from Aurobindo advising that Aurobindo had filed a supplement or amendment to its earlier filed ANDA with the FDA for generic versions of SOLODYN® in 45mg, 65mg, 90mg, 115mg and 135mg strengths. Aurobindo has not advised us as to the timing or status of the FDA's review of its filing, or whether Aurobindo has complied with FDA requirements for proving bioequivalence. Aurobindo's Paragraph IV Patent Certification alleges that our newly issued U.S. Patent No. 7,919,483 (the "483 Patent"), which was issued to us by the USPTO on April 15, 2011, will not be infringed by Aurobindo's manufacture, use, sale and/or importation of the products for which the supplement or amendment was submitted. The expiration date for the 483 Patent is in February 2027. We are evaluating the details of Aurobindo's certification letter and considering our options. Aurobindo's submission amends an ANDA already subject to a 30-month stay. As such, we believe that the amendment cannot be approved by the FDA until after the expiration of the 30-month period or a court decision that the patent is invalid or not infringed.

Nycomed VANOS® Litigation

On April 7, 2010, we received a Paragraph IV Patent Certification from Nycomed US Inc. advising that Nycomed US Inc. had filed an ANDA with the FDA for a generic version of VANOS®. Nycomed US Inc. has not advised us as to the timing or status of the FDA's review of its filing, or whether it has complied with FDA requirements for proving bioequivalence. Nycomed US Inc.'s Paragraph IV Patent Certification alleges that our U.S. Patent Nos. 6,765,001 (the 001 Patent) and 7,220,424 (the 424 Patent) will not be infringed by Nycomed US Inc.'s

manufacture, use, sale, offer for sale or importation of the product for which the ANDA was submitted.

Table of Contents

On May 19, 2010, we filed suit against Nycomed US Inc. and Nycomed GmbH (together, hereunder "Nycomed") in the United States District Court for the Southern District of New York and the United States District Court for the District of Delaware seeking an adjudication that Nycomed has infringed one or more claims of our 001 Patent, 424 Patent and U.S. Patent No. 7,217,422 (the "422 Patent") by submitting the ANDA to the FDA. The relief we requested includes a request for a permanent injunction preventing Nycomed from infringing the patents by selling a generic version of VANOS® prior to the expiration of the asserted patents. On August 3, 2010, Nycomed responded in the New York action by filing an answer, affirmative defenses, and counterclaims alleging that the patents-in-suit are invalid, unenforceable, and will not be infringed by Nycomed's proposed generic version of VANOS®, and a motion to dismiss certain claims related to the patents-in-suit. On August 3, 2010, Nycomed responded in the Delaware action by filing a motion to transfer the Delaware action to New York and a motion to dismiss certain claims related to the patents-in-suit. We responded to Nycomed's motions and pleadings on December 15, 2010.

On December 23, 2010, Nycomed filed an amended answer and counterclaims in the New York action alleging only invalidity and noninfringement of the patents-in-suit. On January 14, 2011, we filed an answer to Nycomed's amended counterclaims in the New York action denying that any of the asserted patents are invalid or not infringed. On January 19, 2011 and January 24, 2011, the New York court endorsed the parties' stipulations withdrawing all pending motions.

On January 19, 2011, the Delaware court endorsed the parties' stipulation withdrawing Nycomed's pending motion to dismiss and ordering Nycomed to answer or otherwise respond to the complaint. On February 2, 2011, Nycomed filed an answer with affirmative defenses alleging that the patents are invalid, unenforceable, and will not be infringed by Nycomed's proposed generic version of VANOS®. On March 31, 2011, the Delaware Court granted Nycomed's motion to transfer the Delaware action to New York. On May 23, 2011, the New York Court consolidated the Delaware action with the New York action and entered a scheduling order. Pursuant to the Court's schedule, discovery is set to close on May 4, 2012, and the parties are scheduled to submit a proposed Pretrial Order on June 1, 2012.

On December 15, 2010, we filed a new complaint for patent infringement against Nycomed US Inc. in the United States District Court for the District of Delaware. Our new complaint seeks an adjudication that Nycomed US's filing of its ANDA for fluocinonide cream 0.1% infringes one or more claims of our U.S. Patent No. 7,794,738 (the "738 Patent"). On February 15, 2011, Nycomed responded by filing a motion to transfer the new Delaware action to New York, as well as a motion to dismiss for failure to state a claim and lack of subject matter jurisdiction. Medicis opposed both motions on March 4, 2011, and Nycomed replied on April 12, 2011. On June 16, 2011, the Delaware Court granted Nycomed's motion to transfer the case to New York. On July 19, 2011, Nycomed withdrew its motion to dismiss. On July 27, 2011, the New York Court consolidated this action with the other New York actions. Nycomed is scheduled to answer the complaint on August 12, 2011.

Stiefel VELTIN Litigation

On July 28, 2010, we filed suit against Stiefel Laboratories, Inc., a subsidiary of GlaxoSmithKline plc ("Stiefel"), in the United States District Court for the Western District of Texas - San Antonio Division seeking a declaratory judgment that the manufacture and sale of Stiefel's acne product VELTIN Gel, which was approved by the FDA in 2010, will infringe one or more claims of our U.S. Patent No. RE41,134 (the "134 Patent") covering our product ZIANA® Gel, a prescription topical gel indicated for the treatment of acne that was approved by the FDA in November 2006. The 134 Patent is listed in the FDA's *Approved Drug Products with Therapeutic Equivalence Evaluations* (Orange Book) and expires in February 2015. We have rights to the 134 Patent pursuant to an exclusive license agreement with the owner of the patent. The relief we requested in the lawsuit includes a request for a permanent injunction preventing Stiefel from infringing the 134 Patent by engaging in the commercial manufacture, use, importation, offer to sell, or sale of any therapeutic composition or method of use covered by the 134 Patent, including such activities relating to VELTIN, and from inducing or contributing to any such activities. On October 8, 2010, we and the owner of the 134 Patent filed a motion for a Preliminary Injunction seeking to enjoin sales of VELTIN. The motion for Preliminary Injunction remains pending.

Actavis ZIANA® Litigation

On March 30, 2011, we received a Paragraph IV Patent Certification from Actavis Mid Atlantic LLC (Actavis) advising that Actavis has filed an ANDA with the FDA for a generic version of ZIANA® (clindamycin

Table of Contents

phosphate 1.2% and tretinoin 0.025%) Gel. Actavis has not advised us as to the timing or status of the FDA's review of its filing, or whether Actavis has complied with FDA requirements for proving bioequivalence. Actavis Paragraph IV Patent Certification alleges that our U.S. Patent Nos. RE41,134 (the 134 Patent) and 6,387,383 (the 383 Patent) will not be infringed by Actavis' manufacture, use and/or sale of the product for which the ANDA was submitted. The expiration date for the 134 Patent is in 2015, and the expiration date for the 383 Patent is in 2020. On May 11, 2011, we filed suit against Actavis in the United States District Court for the District of Delaware. The suit seeks an adjudication that Actavis has infringed one or more claims of the 134 Patent and the 383 Patent by submitting its ANDA to the FDA. The relief we requested includes a request for a permanent injunction preventing Actavis from infringing the asserted claims of the 134 Patent and the 383 Patent by engaging in the commercial manufacture, use, offer to sell, or sale within the U.S., or importation into the U.S., of any chemical entity, therapeutic composition, or method of use claimed by the 134 Patent and the 383 Patent, and from inducing or contributing to such activities, prior to the expiration of the patents-in-suit. As a result of the filing of the suit, we believe that the ANDA cannot be approved by the FDA until after the expiration of the 30-month stay period or a court decision that the patents-in-suit are invalid or not infringed.

Acella TRIAZ® Litigation

On August 19, 2010, we filed suit against Acella Pharmaceuticals, Inc. (Acella) in the United States District Court for the District of Arizona based on Acella's manufacture and offer for sale of benzoyl peroxide foaming cloths which we believe infringe one or more claims of our U.S. Patent No. 7,776,355 (the 355 Patent) covering certain of our products, including TRIAZ® (benzoyl peroxide) 3%, 6% and 9% Foaming Cloths indicated for the topical treatment of acne vulgaris. The 355 Patent was issued to us by the USPTO on August 17, 2010 and expires in June 2026. The relief we requested in the lawsuit includes a request for a Permanent Injunction preventing Acella from infringing the 355 Patent by engaging in the manufacture, use, importation, offer to sell, or sale of any products covered by the 355 Patent, including Acella's benzoyl peroxide foaming cloths, and from inducing or contributing to any such activities. Acella filed with the USPTO a request for ex parte reexamination of the 355 Patent, and filed with the Court a request that the litigation be stayed for the duration of the reexamination. Both the request for reexamination and the request for a stay were initially denied. Acella resubmitted its request for reexamination to the USPTO, which was granted on December 15, 2010. Acella again requested that the case be stayed pending reexamination, and the Court again denied Acella's request. We filed a motion for a Preliminary Injunction on December 10, 2010. The hearing on the Preliminary Injunction motion was to be combined with a Markman Hearing that was also scheduled for February 23, 2011. At a Markman Hearing, a court determines the scope of the patent's claims. The Court held only the Markman Hearing on February 23, 2011, and deferred the hearing on the Preliminary Injunction motion until March 29, 2011. At the Markman Hearing, the Court determined the scope of the patent's claims. Due to the need to postpone the March 29, 2011 hearing on the Preliminary Injunction due to scheduled conflicts, we withdrew our motion for a Preliminary Injunction in favor of a motion for an expedited trial. The case is now set for trial in January 2012.

LOPROX® Patent Litigation

On July 19, 2011, we filed lawsuits against each of Perrigo Company, Inc. (Perrigo), Nycomed U.S., Inc. (hereunder Nycomed), and Taro Pharmaceuticals U.S.A., Inc. and Taro Pharmaceutical Industries, Ltd. (together, Taro, and collectively with Perrigo and Nycomed, the Defendants) in the United States District Court for the Southern District of New York. Each of the lawsuits seeks an adjudication that the respective Defendant is infringing one or more claims of our U.S. Patent No. 7,981,909 (the 909 Patent) by making, using, offering for sale, selling in the U.S. or importing, without authority, a generic version of LOPROX® Shampoo (ciclopirox) 1%. Perrigo, Nycomed and Taro received FDA approval for generic ciclopirox 1% shampoos on or about February 16, 2010, May 25, 2010 and February 23, 2011, respectively. The relief we requested in each of the lawsuits includes damages and a request for a permanent injunction preventing the respective Defendant from selling a generic version of LOPROX® prior to the expiration of the 909 Patent. We have not yet effected formal service of the complaints.

The information set forth under Legal Matters in Note 17 in the notes to the condensed consolidated financial statements, included in Part I, Item I of this Report, is incorporated herein by reference. The pending proceedings described in this section and in Legal Matters in Note 17 in the notes to the condensed consolidated financial

statements included in Part I, Item I of this Report involve complex questions of fact and law and will require the expenditure of significant funds and the diversion of other resources to prosecute and defend. The results of legal proceedings are inherently uncertain, and material adverse outcomes are possible. The resolution of

Table of Contents

intellectual property litigation may require us to pay damages for past infringement or to obtain a license under the other party's intellectual property rights that could require one-time license fees or ongoing royalties, which could adversely impact our product gross margins in future periods, or could prevent us from manufacturing or selling some of our products or limit or restrict the type of work that employees involved in such litigation may perform for us. From time to time we may enter into confidential discussions regarding the potential settlement of pending litigation or other proceedings; however, there can be no assurance that any such discussions will occur or will result in a settlement. The settlement of any pending litigation or other proceeding could require us to incur substantial settlement payments and costs. In addition, the settlement of any intellectual property proceeding may require us to grant a license to certain of our intellectual property rights to the other party under a cross-license agreement. If any of those events were to occur, our business, financial condition and results of operations could be materially and adversely affected.

Item 1A. Risk Factors

We operate in a rapidly changing environment that involves a number of risks that could materially and adversely affect our business, financial condition, prospects, operating results or cash flows. For a detailed discussion of the risk factors that should be understood by any investor contemplating investment in our stock, please refer to Part I, Item 1A Risk Factors in our Annual Report on Form 10-K for the year ended December 31, 2010.

There are no material changes from the risk factors previously disclosed in Part I, Item 1A Risk Factors in our Annual Report on Form 10-K for the year ended December 31, 2010.

Table of Contents

Item 6. Exhibits

| | |
|----------------|--|
| Exhibit 10.1+ | Medicis Pharmaceutical Corporation Supplemental Executive Retirement Plan |
| Exhibit 10.2+ | Employment Agreement between the Company and Jonah Shacknai, dated June 24, 2011 |
| Exhibit 10.3 | Medicis Pharmaceutical Corporation Amended and Restated 2006 Incentive Award Plan ⁽¹⁾ |
| Exhibit 10.4+ | Form of Stock Option Agreement for Medicis Pharmaceutical Corporation Amended and Restated 2006 Incentive Award Plan |
| Exhibit 10.5+ | Form of Amendment to Stock Option Award Agreement for Medicis Pharmaceutical Corporation Amended and Restated 2006 Incentive Award Plan |
| Exhibit 10.6+ | Amendment No. 1 to the Medicis 1992 Stock Option Plan |
| Exhibit 10.7+ | Amendment No. 1 to the Medicis 1995 Stock Option Plan |
| Exhibit 10.8+ | Amendment No. 2 to the Medicis 1996 Stock Option Plan |
| Exhibit 10.9+ | Amendment No. 3 to the Medicis 1998 Stock Option Plan |
| Exhibit 31.1+ | Certification by the Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 |
| Exhibit 31.2+ | Certification by the Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 |
| Exhibit 32.1++ | Certification by the Chief Executive Officer and the Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 |
| Exhibit 101++* | The following financial information from Medicis Pharmaceutical Corporation's Quarterly Report on Form 10-Q for the quarter ended June 30, 2011, formatted in XBRL (Extensible Business Reporting Language) includes: (i) the Condensed Consolidated Balance Sheets as of June 30, 2011 and December 31, 2010, (ii) the Condensed Consolidated Statements of Income for each of the three-month and six-month periods ended June 30, 2011 and 2010, (iii) the Condensed Consolidated Statements of Cash Flows for each of the six-month periods ended June 30, 2011 and 2010, and (iv) the Notes to the Condensed Consolidated Financial Statements. |

+ Filed herewith

++ Furnished herewith

* Pursuant to applicable securities laws and regulations, we are deemed to have complied with the reporting obligation relating to the submission of interactive data files in such exhibits and are not subject to liability under any anti-fraud provisions of the federal securities laws as long as we have made a good faith attempt to comply with the submission requirements and promptly amend the interactive data files after becoming aware that the interactive data files fail to comply with the submission requirements. Users of this data are advised that, pursuant to Rule 406T, these interactive data files are deemed not filed and otherwise are not subject to liability.

- (1) Incorporated by reference to Appendix A to the Company's Definitive Proxy Statement for the 2011 Annual Meeting of Stockholders filed with the SEC on April 6, 2011.

Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

**MEDICIS PHARMACEUTICAL
CORPORATION**

Date: August 9, 2011

By: /s/ Jonah Shacknai
Jonah Shacknai
Chairman of the Board and
Chief Executive Officer
(Principal Executive Officer)

Date: August 9, 2011

By: /s/ Richard D. Peterson
Richard D. Peterson
Executive Vice President,
Chief Financial Officer and Treasurer
(Principal Financial and Accounting
Officer)

57